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1 
GENERAL INTRODUCTION
Parts of the general introduction are based on: 
Adipokines: a link between obesity and dementia? Kiliaan A.J., Arnoldussen I.A.C. and Gustafson D.R. (2014). 
The Lancet Neurology 13(9): 913-923.
Obesity and dementia: adipokines interact with the brain. Arnoldussen I.A.C., Kiliaan A.J., and 
Gustafson D.R. (2014). European Neuropsychopharmacol 24 (12): 1982-99.
Impact of DHA on metabolic diseases from womb to tomb. Arnoldussen I.A.C. and Kiliaan A.J. (2014). 
Marine Drugs 12 (12):6190-212.
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Chapter 1
General introduction
Worldwide, obesity has reached epidemic proportions, and each year obesity or 
obesity-related-diseases lead to the death of 2.8 million adults (1). Obesity has an 
undefined aetiology, but is generally caused by imbalance of energy intake versus 
energy output. This imbalance results in excessive, mainly white adipose tissue 
(WAT) accumulation, adiposity. Adiposity may eventually have an adverse effect on 
human health, which can evolve in adiposity related diseases such as cardiovascular 
disease, type 2 diabetes mellitus (T2DM) and even cognitive impairment and 
dementia (1-3). Individuals are considered obese when their body mass index 
(BMI) exceeds 30.0 kg/m2. BMI grossly reflects total WAT during adulthood (4). 
Although, particularly in older individuals, BMI may not be an accurate marker as 
aging is characterized by lean body mass loss and WAT increase without gaining 
weight, a phenomenon that is not captured by BMI (5). In addition, the amount of 
visceral adipose tissue is associated with higher waist circumference (WC) or waist 
hip ratio (WHR), and therefore this has been another rationale for determining 
central body adiposity (6-8). 
Fatty acids
Intake of diets with a high content of saturated fat (HFD) or high fat and high 
carbohydrates (HFHC) are considered to be important contributing factors 
of adiposity. Moreover, high intake of saturated fatty acids is associated with 
development of non-alcoholic fatty liver disease, hyperlipidemia, and a low state 
of chronic adipose inflammation characterized by a high level of macrophages and 
pro-inflammatory cytokines (9-11). Hyperlipidemia, reinforced by inflammatory 
processes, disrupts vascular function resulting in for instance hypertension, 
atherosclerosis, and cardiovascular disease (12, 13). Thus, high intake of HFD and 
HFHC can contribute to the development of adiposity and cardiovascular disease. 
On the other hand, uptake of adequate levels of saturated and essential unsaturated 
fatty acids from dietary sources is indispensable as they serve as building blocks 
for hormones and phospholipids. For instance, the long-chain polyunsaturated 
fatty acids (LCPUFAs), docosahexaenoic acid (DHA) and arachidonic acid 
(ARA) are essential components of phospholipids, can have anti-inflammatory 
effects, and improve vascular function. Phospholipids form the lipid bilayer of 
neuronal membranes therewith maintaining optimal membrane fluidity and signal 
transmission (Table 1)(14, 15). These LCPUFAs have potency in the prevention 
and treatment of adiposity and adiposity-related-diseases as for instance DHA 
and ARA can modulate WAT storage, reduce inflammatory processes, improve 
endothelial function, cerebrovascular reactivity and memory consolidation (16-19). 
In addition, promising results are found in examining the short chain fatty acid, 
butyrate as treatment for adiposity and adiposity-related-diseases (20). Butyrate 
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is a product of bacterial fermentation of mainly indigestible plant polysaccharides 
and resistant starch in the colon. Obese individuals have a decreased concentration 
of butyrate-producing bacteria and dietary butyrate intake may protect against 
diet-induced adiposity, improve insulin sensitivity and increases energy expenditure 
(21-24). Moreover, butyrate has anti-inflammatory properties and is involved in 
the regulation of liver lipogenesis, adipocyte differentiation, and energy intake 
(23). Thus, dietary interventions such as LCPUFAs, butyrate or even indigestible 
fiber rich diets, could contribute to the prevention and decline of adiposity-relat-
ed-diseases and adiposity. 
12
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Table 1. DHA and metabolic diseases through lifetime. DHA: docosahexaenoic acid; EPA: 
eicosapentaenoic acid; DPA: docosapentaenoic acid; CLA: conjugated linoleic acids; CHF: 
congestive heart failure; T2DM: type 2 diabetes mellitus; NIDDM: non-insulin-dependent 
diabetes mellitus; VLDL: very-low-density-lipoproteïnen; N: number of participants; Age is 
represented in years and in Mean±SD. Mean age >4 and ≤12 Year childhood; Mean age 
>12 and ≤21 adolescence; Mean age >21 and ≤60  adulthood; Mean age >60  elderly.
Adiposity and brain function
Adiposity has been associated with alterations in brain structure and function, 
cognitive deficits, and even dementia and Alzheimer’s disease (AD) (50-55). For 
instance, loss of gray and white matter integrity, functional connectivity, and 
cortical thickness are observed in children, adolescents and adults (52, 54, 56-62). 
Moreover, abnormalities in functional brain regions found in obese adults such 
as in the amygdala, hippocampus, and frontal cortex (63, 64). Age is crucial in 
examining the association between adiposity and the brain (Fig. 1 and 2) as 
individuals with midlife obesity have a higher risk of developing dementia in late 
life (65-70), whereas late life obesity seems to reduce dementia risk (71-74). In 
addition, adiposity may lead to damage manifested as structural changes similar 
to those seen in normal aging (75, 76). Exact biological pathways linking adiposity 
to brain processes are multi-factorial and still unrevealed (77-81). In this thesis we 
will discuss two pathways via which adiposity might affect brain structure, function 
and cognition with emphasis on the (cerebro)vascular pathway and adipokines. 
13
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Figure 1. Possible life course trajectory of BMI in association with dementia MCP-1=monocyte 
chemotactic protein-1. PAI-1=plasminogen activator inhibitor-1. Reviewed adipokines 
regulate: energy balance and metabolism; thrombosis and hypertension; inflammation.
(Cerebro) vascular pathway
Subsequent to the dramatic rise of adiposity, the prevalence of insulin resistance and 
premature cardiovascular disease increased (82). Insulin resistance plays a central 
role in the pathogenesis of T2DM and develops long before the onset of the disease 
(83). Individuals with peripheral insulin resistance often show reduced insulin 
sensitivity in the brain, which can affect cognitive functioning (84, 85). Two-third 
of adults in the U.S. are diagnosed as overweight or obese of which 26 million have 
T2DM (86). Moreover, two-third of severely obese children younger than 12-years 
of age, develop cardiovascular risk factors (87), and obese individuals show a 
significantly increased risk of cardiovascular disease as well (86). Importantly, 
particularly clustering of adiposity, T2DM and cardiovascular risk factors has 
been linked to alterations in vasculature (e.g. arterial stiffness, hypertension and 
atherosclerosis), hypoperfusion, structural brain changes, cognitive impairment, 
and dementia (Fig. 1 and 2)(85, 88). 
14
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We hypothesize that adiposity can induce (cerebro)vascular changes such as 
arterial stiffness, inflammation and hypoperfusion, which can subsequently disrupt 
brain structure and function, and increase the risk for cognitive impairment and 
dementia. In more detail, the brain relies on perfusion as a constant cerebral blood 
flow (CBF) ensures constant oxygen and glucose supply and drainage of ‘waste 
products’. In humans, overweight and obese individuals often have a decreased 
CBF (18). A decreased CBF, or hypoperfusion may be a result of reduced small 
vessel density, inflammation, arterial stiffness, atherosclerosis of the large and small 
vessels around/within the brain, and/or impaired vasodilation. Hypoperfusion can 
result in reduced gray and white matter volumes, which subsequently may evolve 
in cognitive impairment (18, 89, 90). Neuroimaging in obese individuals revealed 
structural brain changes like white and gray matter abnormalities, already at a very 
young age (89-92). These structural brain abnormalities may evolve in functional 
alternations as adiposity is associated with poorer executive functioning skills such 
as inhibitory control and working memory, and subsequently increases the risk to 
develop cognitive impairment and dementia (3, 93-95). 
Figure 2. The trajectory of body mass index over the life course by chronological age and 
potential roles of adipokines. PAI-1=plasminogen activator inhibitor-1. HGF=hepatocyte 
growth factor. NGF=nerve growth factor. MCP-1=monocyte chemotactic protein-1. BMI=body 
mass index. ADSC=adipose-derived stem cells.
Adipokines 
WAT is a complex tissue consisting of multiple cell types with multiple cellular 
phenotypes depending on cell composition and location (96). WAT secretes hundreds 
of polypeptides, adipokines, and includes cytokines, acute phase reactants, growth 
factors and other inflammatory mediators, adipose tissue hormones such as leptin, 
and other chemical messengers (51, 77, 97). The adipokines secreting profile is fat 
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depot-specific, which is coherent with differences in adipocyte morphology and the 
local milieu (98-100). Adipokines act in autocrine, paracrine, or endocrine ways 
(101), and many affect processes in the periphery and the central nervous system. 
In addition, brown, epicardial and pancreatic adipose tissue appear to have unique 
adipokine profiles (102-104). Adipokine release may be dysregulated in obesity, 
possibly because the adipose tissue may be ‘diseased’. Since neurodegenerative and 
vascular processes observed in dementia affect several brain regions and nuclei 
(105), the action of adipokines might be altered during neurodegenerative and 
vascular events, and may even feedback to contribute to neurodegeneration. 
Over 700 adipokines have been reported in response to specific chronic or acute 
stimuli or at rest (106). In table 2 and 3 we present adipokines and their primary 
known function such as metabolism (e.g. leptin, adiponectin, adipsin), vascular 
function (e.g. C-reactive protein, serum amyloid A, plasminogen activator 
inhibitor-1), and inflammatory processes (e.g. interleukins, monocyte chemotactic 
protein-1) (77, 88). Each may possess more than one function, and these functions 
do overlap (107). Figure 3 represents an overview of possible pathways of 
adipokines affecting the brain. Adipokines are extensively reviewed in Kiliaan et 
al. and Arnoldussen et al., and therefore we will shortly discuss the most studied in 
humans (77,88).
Leptin, a satiety hormone regulates food intake and energy expenditure (108, 109). 
Observations from human population studies in late life suggest that high leptin 
levels and high BMI are associated with lower dementia risk when measured within 
10 years of clinical dementia diagnosis (110, 111). Leptin can affect hippocampal 
memory formation as it enhances N-methyl-D-aspartate receptor function and 
subsequently enhances long term potentiation formation at hippocampal CA1 
synapses and rapidly remodels dendrites (112-114). Moreover, leptin can affect 
vascular function by enhancing platelet aggregation and arterial thrombosis, 
promoting angiogenesis and inducing proliferation, and migration of vascular 
smooth muscle cells (115-117). Leptin seems to enhance the calcification of vascular 
cells, making also the arterial wall a target of leptin (117). While leptin levels may 
trend with BMI in relation to dementia, given the strong correlation between them, 
leptin may also have an independent role in health of the ageing brain. 
Adiponectin modulates inflammatory responses, energy expenditure, food intake, 
and a number of metabolic processes including glucose regulation and fatty 
acid catabolism (118). Adiponectin protects plaque rupture by the inhibition of 
matrix metalloproteinase function (117). Moreover, endothelium-dependent 
vasoreactivity is impaired in people with hypoadiponectinemia, which might be 
at least one cause of hypertension in visceral obesity, probably by inhibiting the 
expression of adhesion molecules (117, 119). 
16
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Table 2. A sampling of adipokines involved in energy balance and metabolism, inflammation, 
and thrombosis and hypertension.
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Table 3. Overview of reviewed adipokines, their level in obesity, ability to cross the BBB, 
and roles in the periphery, non-obese and obese brain.  ; Plasma levels of adipokine are 
upregulated in obesity. 

; Plasma levels of adipokine are downregulated.
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A chronic low inflammation state in the adipose tissue is established in case of 
excessive WAT accumulation (adiposity), partly mediated via production of 
pro-inflammatory adipokines such as tumor necrosis factor alpha (TNF-α) and 
interleukin-6 (IL-6) (11). Higher plasma IL-6 levels are associated with lower 
hippocampal gray matter volume (186), and excessive production of TNF-α by 
WAT could decrease adult neurogenesis by halting cell division of hippocampal 
progenitor cells, impair long term potentiation facilitation with subsequent 
memory and learning deficits (77). The release of pro-inflammatory cytokines such 
as TNF-α and IL-6 might have a pivotal role in the relationship between oxidative 
stress and endothelial dysfunction (117). Inflammation might have an essential 
role in the development of insulin resistance, the initiation and progression of 
atherosclerotic lesions and plaque disruption. Moreover, IL-6 and TNF-α are the 
main inducers of C-reactive protein (CRP) secretion in the liver. CRP is a marker 
of low-grade inflammation, and it has been suggested that this protein has a role in 
the pathogenesis of atherosclerotic lesions in humans (187). 
Mouse models
Studies in humans can illustrate an association between adiposity, cognitive 
function, and related biological variables. However, the exact mechanism behind 
adiposity related to cognitive impairment cannot be clarified, and therefore 
translational animal studies are needed. Animal models provide the opportunity 
to test the efficacy of potential innovative supplementary dietary components 
in adiposity, anatomical, metabolic, and neurochemical detail. The low-density 
lipoprotein receptor knock-out Leiden (LDLr-/-) and apolipoprotein E3 Leiden 
(ApoE3*Leiden) mouse models were chosen in our research because of their 
adiposity mimicking features when exposed to a diet containing high levels of 
fat and/or sucrose, such as hyperlipidemia. Secondly, both mouse models were 
chosen for their vulnerability to develop cardiovascular risk factors often found in 
obese individuals. ApoE3*Leiden transgenic mice have a rare dominant-negative 
mutation in the human APOE3 gene and therefore a humanized lipoprotein 
metabolism. ApoE*3Leiden mice are highly responsive to fat-, sugar- and 
cholesterol-containing diets, resulting in strongly elevated plasma cholesterol and 
triglyceride levels with a prominent increase in very low density lipoprotein- and 
low-density lipoprotein (LDL)-sized lipoprotein fractions (188). LDLr-/- mice 
lack the functional low-density lipoprotein receptor (LDLr). The LDLr mediates 
the clearance of cholesterol transported through the bloodstream in low-density 
lipoproteins by endocytosis (189). LDLr-/- Leiden mice develop obese features on 
a HFD including hypertension, hyperlipidemia, hypercholesterolemia, increased 
body weight, and atherosclerosis (190, 191).
20
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Figure 3. Effects of adipokines in the periphery and brain in adiposity.  Fat cells produce 
and secrete adipokines like, leptin (red), PAI-1 (blue), angiotensinogen (green), adiponectin 
(pink), TNF-α (turquoise) and IL-6 (purple). In the periphery, TNF-α and IL-6 stimulate 
inflammation; these adipokines trigger the liver to produce acute phase proteins. Adiponectin 
attenuates the inflammatory response by inhibiting the production of TNF-α and IL-6. 
Furthermore, adiponectin modulates inflammatory responses, energy expenditure (CNS 
and periphery), food intake (CNS) and a number of metabolic processes, including glucose 
regulation and fatty acid catabolism. Angiotensinogen increases blood pressure. PAI-1 inhibits 
fibrinolysis and also stimulates the inflammatory response. Leptin increases energy expenditure 
and decreases food intake. Only of leptin, TNF-α and Il-6 it is known they are able to cross the 
BBB and affect, positively or negatively depending on concentration and environment, brain 
processes such as food intake, synaptic plasticity, learning and memory, and development of 
dementia. Furthermore, angiotensinogen, PAI-1, IL-6, TNF-α are also produced by neurons, 
astrocytes and microglia, and several theories exist that leptin and adiponectin might also be 
produced in the central nervous system. Within the brain these adipokines can be involved 
in the regulation of food intake, neurogenesis, neuroprotection, neuroinflammation, synaptic 
plasticity, memory and learning processes and the onset and progression of dementia. 
Abbreviations: PAI-1: plasminogen activator inhibitor-1; IL-6: interleukin-6; TNF-α:tumor 
necrosis factor-alpha; CNS: central nervous system; BBB: blood brain barrier; +: increases/
stimulates; -:decreases/inhibit.
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Thesis overview
In this thesis we aim to elucidate the ‘adiposity-brain-axis’ involving dietary fatty 
acids (ARA, DHA and butyrate), (cerebro)vasculature, adipokines, and the effect of 
aging on these processes. In detail the aims of this thesis are:
•	 Investigate the ability and mechanisms by which specific dietary fatty acids 
can protect against and counteract HFD induced obesity in mouse models.
•	 Indicate adiposity associations in aging.
•	 Examine adiposity in relation to changes in brain structure and dementia 
in humans.
In chapter 2 we studied the effect of early life dietary LCPUFAs (ARA and 
DHA) intake in mild-obese in transgenic ApoE3*Leiden mice. A broad and 
multidisciplinary experimental approach was used to examine energy metabolism, 
brain structure, cerebral circulation, and cognition. Therefore, we assessed 
immunohistochemical studies on fat depots, liver, and brain tissue. Moreover, we 
tested these mice in behavioral experiments like the open field test and Morris 
water maze. Neuroimaging was used to determine CBF (using arterial spin labeling 
(ASL)), functional connectivity (using resting state fMRI), and gray and white 
matter integrity (using diffusion tensor imaging (DTI)). We hypothesized that 
the intake of ARA and DHA could attenuate the high fat diet induced effects on 
metabolism, cerebral blood flow, brain structure and cognition. 
The aim of the study in chapter 3 was to obtain detailed insights in the effects 
of the short chain fatty acid, butyrate on mid- and late life adiposity in LDLr-/- 
Leiden mouse model. We hypothesized that the effects of a HFD and butyrate 
would differ in mid- and late life, according to findings in humans. Metabolism, 
inflammatory processes, and brain function were extensively examined using 
blood and microbiome analyses, immunohistochemistry at liver, adipose and brain 
tissue, the cognitive test the Morris water maze to indicate learning and memory 
processes, and MRI determining CBF, functional connectivity and brain structure. 
In the RUN DMC study (chapter 4) we examined adiposity indicators (body mass 
index (BMI), waist circumference (WC), and blood leptin and total adiponectin 
levels) in association with brain volumes and components of cerebral Small 
Vessel Disease (cSVD) in adults age ≥50 years enrolled in the Radboud University 
Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort (RUN DMC 
study). The RUN DMC study provides a nine year follow-up starting in 2006 of 
Dutch men and women diagnosed with cerebral small vessel disease.
In the study described in chapter 5 we analyzed in Gothenburg studies if 
anthropometric parameters as BMI and waist-hip ratio, and serum adipokines 
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levels like adiponectin and leptin could predict dementia risk in older Swedish 
adults over a 10 year period. In addition, we examined whether these associations 
are different between older men and women. These Gothenburg studies provided 
us a 10-year prospective population-based study of 70 years and older inhabitants 
of Gothenburg, Sweden. 
Chapter 6 and 7 are dedicated to the general discussion and a summary of all 
study findings, and we propose suggestions for future studies to gain a better 
understanding of adiposity and brain function. 
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 STRUCTURE AND FUNCTION IN DIET INDUCED OBESITY
Arnoldussen I.A.C.
Zerbi V.
Wiesmann M.
Noordman R.H.J.
Bolijn S.
Mutsaers M.P.C.
Dederen P.J.W.C.
Kleemann R.
Kooistra T.
van Tol E.A.F.
Gross G.
Schoemaker M.H.
Heerschap A.
Wielinga P.Y.
Kiliaan A.J. 
(2016) Journal of Nutritional Biochemistry 30: 177-188.
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Abstract 
Worldwide, the incidence of obesity is increasing at an alarming rate, and the 
number of children with obesity is especially worrisome. These developments raise 
concerns about the physical, psychosocial and cognitive consequences of obesity. It 
was shown that early dietary intake of arachidonic acid (ARA) and docosahexaenoic 
acid (DHA) can reduce the detrimental effects of later obesogenic feeding on lipid 
metabolism and adipogenesis in an animal model of mild obesity. 
In the present study, the effects of early dietary ARA and DHA on cognition and 
brain structure were examined in mildly obesogenic ApoE*3Leiden mouse model. 
We used cognitive tests and neuroimaging during early and later life. During their 
early development after weaning (4-13 weeks of age), mice were fed a chow diet 
or ARA and DHA-diet for eight weeks, and then switched to a high fat and high 
carbohydrates (HFHC) diet for 12 weeks (14-26 weeks of age). 
A HFHC-diet led to increased energy storage in white adipose tissue, increased 
cholesterol levels, decreased triglycerides levels, increased cerebral blood flow, and 
decreased functional connectivity between brain regions as well as cerebrovascular 
and gray matter integrity. ARA and DHA intake reduced the HFHC diet-induced 
increase in body weight, attenuated plasma triglycerides levels and improved 
cerebrovasculature, gray matter integrity and functional connectivity in later life. 
In conclusion, a HFHC diet causes adverse structural brain and metabolic 
adaptations, most of which can be averted by dietary ARA and DHA intake early in 
life supporting metabolic flexibility and cerebral integrity later in life.
27
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Introduction
Each year, obesity or obesity-related conditions lead to the death of 2.8 million 
people around the world (1). Besides the well-known metabolic complications, 
obesity is associated with cognitive dysfunction and changes in the central nervous 
system particularly in the areas of executive function, attention and concentration 
(77, 88, 94, 192-194). For example, visuospatial organization is affected in 
overweight children, and in later life these children often suffer from emotional 
problems (95, 195). It has been shown that obese children also demonstrate an 
impaired neural activity (196). Remarkably, obese children and adolescents have a 
decreased gray matter volume of frontal and limbic lobe regions (197). Therefore, 
novel approaches related to healthy weight development are urgently required.
Animal research has revealed that exposure to high fat diets and high caloric 
diets increases inflammatory signals within the brain and decreases neurogenesis 
(198-200). Diets with a high content of fat and carbohydrates (HFHC) are considered 
to be important contributing factors of overweight and obesity. Promising results 
in animal and human studies show the potency of long-chain polyunsaturated fatty 
acids (LCPUFAs) in the prevention and treatment of obesity and overweight (17, 
26, 28, 29, 201, 202). The amount and ratio of omega-6 and omega-3 LCPUFAs that 
are consumed during childhood may determine the adult metabolic profile and 
risk factors of disease (203). For instance, supplementation with a specific ARA and 
DHA mixture in early life reduces body weight gain, adiposity and adipose tissue 
inflammation later in life in mildly obese mice with a lipoprotein profile comparable 
to humans (202). Moreover, LCPUFAs are essential to support optimal brain and 
visual system development. Docosahexaenoic acid (DHA) and arachidonic acid 
(ARA), belonging to the omega-3 and omega-6 LCPUFAs respectively, are the two 
most abundant LCPUFAs in the brain (reviewed by (204, 205)). 
In this study, we therefore studied the effect of early LCPUFA dietary-intake on 
cognition, brain function and structure in early and later life in ApoE3*Leiden 
transgenic mice in the context of mild diet-induced obesity. These mice have a 
humanized lipoprotein metabolism and develop hyperlipidemia and mild obesity 
on HFHC diets (188, 202, 206). In addition, this mouse model of mild obesity 
development has not been used yet to evaluate brain development and function 
earlier. We used a multi-disciplinary experimental approach in order to examine 
the programming impact of combined dietary ARA and DHA intake in early 
life on a HFHC diet in later life. Furthermore, we performed in vivo and ex vivo 
experiments that cover diet-induced adaptations in energy metabolism, cerebral 
circulation and cognition. For this purpose, translational cognitive tests and 
read-outs were applied that are relevant for the human context. The results of this 
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study are of scientific and societal importance as they further substantiate and 
elucidate the importance of early programming effects of healthy balanced diets 
containing LCPUFAs, capable of maintaining metabolic and cognitive flexibility 
during obesogenic challenges later in life. 
Material and Methods
Animals, diets and study design
Male heterozygous ApoE*3Leiden-transgenic mice were housed in 
individually-ventilated cages (IVC) in conventional animal rooms (relative 
humidity 50–60%, temperature 21°C, light cycle 7 a.m.–7 p.m. (5 mice per cage)) 
in the preclinical imaging centre (PRIME) at the central animal laboratory, 
Radboudumc Nijmegen, the Netherlands. Mice had ad libitum access to acidified 
tap water and food. These mice originated from the SPF breeding stock at TNO 
Metabolic Health Research, Leiden, the Netherlands. The mice carry the mutated 
form of the human apolipoprotein E3 gene, and are considered as a humanized animal 
model for hyperlipidemia, atherosclerosis and mild obesity. The ApoE*3Leiden 
mutation is a rare dominant-negative mutation in the human APOE3 gene, and 
it is characterized by a tandem duplication of codons 120 to 126 and associated 
with familial dysbetalipoproteinemia. Besides the APOE*3-Leiden gene, this 
construct consists of the ApoC1 gene and a promoter element that regulates the 
expression of ApoE and ApoC1 genes (188, 207, 208). ApoE*3Leiden transgenic 
mice have been generated by introducing a human APOE*3Leiden gene construct 
into C57Bl/6 mice. ApoE*3Leiden mice are highly responsive to fat-, sugar-, and 
cholesterol-containing diets resulting in strongly elevated plasma cholesterol and 
triglyceride levels with a prominent increase in VLDL- and LDL-sized lipoprotein 
fractions (188). Of note, female mice are prone to develop high plasma cholesterol 
levels on atherogenic cholesterol-containing Western type diets, while male mice 
are less susceptible and show plasma cholesterol levels < 8 mM (209). Under the 
experimental conditions conducted in our current study, the mice do not develop 
sufficiently high plasma VLDL/LDL cholesterol for development of atherosclerosis.
The total group of 45 ApoE3*Leiden mice was divided into subgroups. During 
the early life period, from 4 to 13 weeks, 30 mice in the first group received a 
standardized chow diet (referred to as: ‘Chow’; Sniff R/M diet V1530, Bio Services 
BV, Uden, The Netherlands). 15 mice were fed a chow diet containing with 0.129% 
(w/w) ARA and 0.088% (w/w) DHA in their early life (referred to as: ‘ARA&DHA’; 
DSM Nutritional Products North America, Columbia, MD, USA). In later life, 
from 14 to 26 weeks, the group on the chow diet was split into a control group 
(N=15), which continued on the chow diet (referred to as: ‘ChowChow’), and 
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an intervention group (N=15) which switched to a HFHC-diet (referred to as: 
‘ChowHFHC’). The ARA&DHA-group (N=15) also switched to the HFHC-diet 
later in life (referred to as: ‘ARA&DHAHFHC’). This HFHC-diet is based on 
the diets used by Madsen et al. (210). Table 1 provides the composition of the three 
diets used. 
Table 1. Diet composition. Chow is a conventional diet (Sniff R/M diet V1530, Uden, The 
Netherlands). In the ARA&DHA diet, the conventional diet is enriched with 0,129% w/w 
C20:4 (n-6) and 0,088% w/w C22:6 (n-3) fatty acids. The high fat and high carbohydrate 
(HFHC) diet is a purified diet with a high concentration of carbohydrates and fat, like for 
instance dextrose, casein and beef tallow (Arie Blok Diets, Woerden, the Netherlands) (50% 
saturated fat, 46% mono-unsaturated fat and 2 % poly-unsaturated fat). ARA = arachidonic 
acid; DHA = docosahexaenoic acid; HFHC = high fat & high carbohydrate; (w/w) = weight 
per weight; kcal% = percent of kilo calorie.
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Blood samples were taken after 5 hours of fasting (8 a.m.–1 p.m.) at 4, 10, 12, 20 
and 26 weeks of age. These blood samples were tested for plasma triglycerides, 
cholesterol, insulin and leptin levels. Individual body weight and food intake (at 
cage level) were monitored over time. To investigate possible changes in cognition 
and brain structure induced by diet in early life, the mice, aged 12-13 weeks, were 
assessed in several cognitive tests and MRI experiments. The following experiments 
were performed: open field, rotarod, object recognition test (ORT), resting state 
functional MRI (rsfMRI), arterial spin labeling (ASL), and diffusion tensor imaging 
(DTI). In early life, all mice were assessed in cognitive tests, and 20 chow and 10 
ARA&DHA fed mice were examined in MRI experiments. Thereafter, the mice 
switched to a HFHC diet. In later life these mice, aged 26 weeks, were assessed in a 
second run of the same cognitive tests and MRI experiments, but only the ORT was 
replaced for the long term memory test, Morris water maze (MWM). Ten mice per 
diet group were assessed for MRI experiments, and fifteen mice per diet group were 
examined during the cognitive tests. At 26 weeks of age, all mice were anesthetized 
and sacrificed by transcardial perfusion with 0.1M phosphate-buffered saline 
(PBS), and thereafter organs like brain, liver and adipose tissue were harvested. An 
overview of the study design is provided in figure 1. 
Figure 1. Study design. In early life, ApoE3*Leiden mice received either a chow diet or an 
ARA&DHA-diet. The first run of cognitive tests was assessed in all mice aged 12 weeks, i.e. 
open field, rotarod and object recognition test. The following week, these mice were assessed 
in MRI-experiments (Chow N=20 and ARA&DHA N=10). At 14 weeks of age, the mice 
switched from diet. All 25 week-old mice were assessed for the second run of cognitive testing, 
and MRI-experiments (N=10 per diet group). All mice aged 26 weeks were anesthetized and 
sacrificed by transcardial perfusion. HFHC: high fat and high carbohydrate diet; rsfMRI: 
resting state functional magnetic resonance imaging; ASL: arterial spin labelling and DTI: 
diffusion tensor imaging.
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Plasma analyses
Total plasma cholesterol and triglyceride levels were measured enzymatically 
using kits number 11489437 and 11488872 (Roche Diagnostics, Almere, The 
Netherlands) following a standardized protocol of Wielinga et al. (202).
Open field
The open field test (OF) was performed to analyze locomotion and exploration. We 
followed a protocol previously described by Janssen et al. (211-213). 
Rotarod
To test sensory-motor integration, all mice were placed on a rotating drum to 
assess in the rotarod test. The rotarod was performed and analyzed following a 
standardized protocol described by Janssen et al. (213). 
Object recognition test
ApoE3*Leiden male mice were assessed in the object recognition test (ORT) to 
examine short term memory. This method was based on literature of Brooks et al., 
Bevins and Besheer (56, 214). In short, subsequent to habituation, two similar objects 
were placed in the box and a mouse was allowed to explore the objects after a 30, 60 
and 120 minutes delay, respectively. All short term memory trials were recorded, 
and afterwards blind and randomized scored using Ethovision (EthoVision XT 8.5, 
Noldus Information Technology, Wageningen, The Netherlands). A mouse was 
considered as an outlier, if it had no interest in the objects during the two memory 
trials, or if it sat at the objects. Preference for the novel object was expressed in 
discrimination ratio, which can be defined as: the time spent exploring the novel 
object minus the familiar object divided by the total object explorer-time.
Morris water maze
Acquisition and probe
The Morris water maze (MWM) was assessed to examine long term memory and 
spatial learning abilities of the ApoE3*Leiden mice aged 25 weeks. Mice had to seek 
a submerged platform located in the North-East (NE) quadrant in a circular pool 
(104 cm diameter) filled with water (21–22ºC; made opaque by the addition of milk 
powder), as previously described by Janssen et al. (213). 
Search strategies
During the MWM acquisition phase, mice use different search strategies in context 
of spatial learning. During subsequent trials mice proceed from random towards 
hippocampus-dependent, and more direct and precise search strategies (215, 216). 
These swimming pathways were analyzed, and classified into seven search strategies 
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in order to indicate hippocampus-dependent and -independent search strategies 
(Ethovision XT 8.5, Noldus Information Technology, Wageningen, Netherlands).
Immunohistochemistry
The left hemisphere of the brain was postfixed in 4% paraformaldehyde for 24 
hours for immunohistochemical purposes. Afterwards the hemispheres were 
stored in 0.1M phosphate buffered saline (PBS) with 0.01% sodium azide (NaN3). 
Coronal brain sections were sectioned using a sliding microtome (Microm HM 
440, Walldorf, Germany) equipped with an object table for freeze sectioning at 
-60ºC gaining 8 series of 30-µm thick sections. The right hemispheres were divided 
into 4 sections and immediately snap frozen and stored in a -80˚C freezer. Adipose 
tissue was also divided and stored for either immunohistochemical or biochemical 
purposes. 
Adipose tissue analysis
Adipose tissues were fixed in formalin, embedded in paraffin and sliced in 5 µm 
sections. The slices were stained with hematoxylin. Briefly, were photographed with 
a Zeiss Imager A2 microscope (Zeiss, Germany) at 20x magnification with Ludl 3-axis 
controlled stepping motor system with a colour digital camera. Quantification was 
performed with ImageJ software (JAVA based public domain, National institutes of 
health, Maryland, USA) which calculated the size of the adipocytes (µm2) for three 
sections of each fat depots, and around the 30-40 adipocytes per section.
Glucose transporter-1 fluorescent immunohistochemistry 
To measure the amount of glucose transporters-1 (GLUT-1) in the blood vessel walls 
in the brain indication for blood vessel integrity, an intensity staining was used. We 
used a free-floating fluorescent staining of GLUT-1 on hippocampal sections of 30 
µm. Sections reserved for the fluorescence GLUT-1 staining were pre-incubated 
for half an hour in PBS-BT followed by the primary incubation overnight with 
rabbit anti-GLUT-1 (1:5000; Millipore, Billerica, Massachusetts, USA) at room 
temperature. After the primary incubation, the sections were rinsed and then 
incubated with the second antibody, donkey anti-rabit-Alexa-445 conjugated 
(1:100 in PBS-BT; Jackson Immuno Research, Suffolk, UK), for three hours in the 
dark. Subsequently, sections were rinsed, mounted on gelatin coated slides and 
air-dried in the dark for two hours. After embedding the sections in Fluorsave the 
sections were stored at 7 °C. Pictures were taken at a 5x magnification with an Axio 
Imager A2 (Zeiss Germany) and the sections were stored for a longer period at -20 
°C. Sections were photographed using a shutter speed of 500 ms at 470 nm to excite 
the fluorescence. ImageJ was used for quantification of amount of positive glucose 
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transporters in blood vessels in the cortex, thalamus and hippocampus (bregma 
-1.7 and -2.46). In addition, the surface and intensity were measured.
Quantitative real-time polymerase chain reaction
The snap-frozen midbrains were used for the analysis of mRNA levels using 
quantitative real-time polymerase chain reaction (qRT-PCR) of: glucose 
transporters-1 (GLUT-1, (217)), preproinsulin (218), insulin receptor (219), leptin 
receptor A (220) and B (221), vascular endothelial growth factor (VEGF, (222)), 
occludin (223). Forward and reverse primer sequences are represented in table 
2. A standardized protocol was used for these analyses as previously described 
by Janssen et al. (213). Per primer a negative control consisting of water instead 
of cDNA was added and per primer one plate was used consisting of both the 
glyceraldehyd 3-phosphate dehydrogenase (GAPDH) and the primer of interest. 
GAPDH is a reference gene serving as a control for general cell activity. The 
quality of the samples was evaluated using the melt curve and amplification plot. 
The StepOne Software version 2.2.2 was used to determine the threshold cycle 
(CT) values. To analyze possible differences between dietgroups CT values were 
normalized by GAPDH and transformed to the comparative CT value via the 
2-ΔCT method (224).
Table 2. Forward and reverse sequences of the primers. GAPDH: glyceralehyde-3-phosphate 
dehydrogenase; GLUT-1: glucose transporters-1; Occludin: tight junction protein; VEGF: 
vascular endothelial growth factor; ObRA: leptin receptor A; ObRB: leptin receptor B and 
InsulinR: insulin receptor; FW: forward; REV: reverse. 
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MRI-experiments
MRI measurements were performed with a 11.7 T Biospec Avance III small animal 
MR system (Bruker BioSpin, Ettlingen, Germany) equipped with an actively 
shielded gradient set of 600 mT/m, and operated by a Paravision 5.1 software 
platform. We used a circular polarized volume resonator for signal transmission 
and an actively decoupled mouse brain quadrature surface coil for signal reception 
(Bruker BioSpin). During the experiment, isoflurane (Nicholas Primal (I) limited, 
London, United Kingdom) was used for anaesthesia (3.5% for induction for 2 
minutes and approximately 1.8% for maintenance in a mixture of oxygen and nitrous 
oxide (1:2)). Respiration of the animal was monitored using a pneumatic cushion 
respiratory monitoring system (Small Animal Instruments Inc., NY, USA). Mice 
were placed in a stereotactic device to immobilize the head. Body temperature was 
measured using a rectal thermometer and maintained at 37 °C using a heated air 
flow device. First, gradient echo images were acquired using previously described 
image parameters (225). Resting state fMRI (rsfMRI) acquisition and analysis 
were performed to assess functional connectivity within specific brain regions 
following a protocol of Zerbi et al.(226). Arterial spin labeling (ASL) was assessed 
to indicate cerebral blood flow (CBF) levels using an established ASL method 
with flow-sensitive alternating inversion recovery (FAIR) technique (227-229). 
ALS method was performed as previously described by (225, 226). Measurements 
were assessed in two standardized gas concentrations, first: 2 O2 : 1 N2O, and the 
second, vasoconstriction inducing concentration, 3 O2 : 0 N2O. CBF values from 
both conditions were used to examine the ability of the cerebrovasculature to adapt 
from a normal condition into a vasoconstrictive condition, which is referred to 
as vasoactivity. To calculate vasoactivity, the normal CBF values were abstracted 
from the vasoconstriction CBF values, and this was then divided by the sum of 
the normal and vasoconstrictive CBF values. To calculate regional CBF we used 
the same protocol as previously described (225). Finally, diffusion tensor imaging 
(DTI) was performed to determine gray and white matter integrity following a 
modified protocol of Zerbi et al. (230). All imaging parameters are represented in 
table 3.
Statistical analysis
A random and double-blind selection procedure was maintained throughout the 
experiment. The results are expressed as means ± standard error of mean (SEM). 
Means were analyzed using repeated measures, univariate or multivariate analysis of 
Analysis of variance (ANOVAs) with Bonferroni correction for multiple testing in 
a statistical program, SPSS20 (IBM SPSS Statistics 20, IBM Corporation, Armonk, 
New York, USA). Diet effects were referred to as significant if the P-value was lower 
than 0.050, and a trend was implied if the P-value was below 0.080 and above 0.050. 
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Statistical analysis were only performed on the basis of tests for normality (231) 
and homogeneity of variance (232). All Data are presented in Mean ± SEM.
Table 3. List of parameters used in MRI experiments
Results
Metabolic parameters
Body weight and food intake
At the start of the experiment, when the mice were four weeks of age, the averaged 
body weight was 14.9 ± 0.36g. Up to 13 weeks, body weight measurements revealed 
that ApoE3*Leiden mice on ARA&DHA-diet had a significantly (P=0.028, 
F(1,43)=5,16) lower body weight compared to the mice on chow-diet (Fig. 2A). 
Food intake was measured per cage (N=3 per diet group), and in early life, from 
4 to 13 weeks of age, these mice consumed about the same amount of chow or 
ARA&DHA-diet (Chow: 4.1±0.052 g diet/mouse/day; ARA&DHA: 3.84±0.052 g 
diet/mouse/day). 
After the diet switch at 14 weeks, mice fed the ARA&DHAHFHC diets tended to 
maintain a lower body weight when compared to ChowHFHC fed mice (P=0.080, 
F(1,28)=3.14) (Fig. 2). The switch to a HFHC-diet caused a significantly reduced 
food intake in these mice in later life, possibly because rodents often maintain an 
iso-caloric eating pattern (ChowChow: 3.13±0.33; ChowHFHC: 1.54±0.33 ; 
ARA&DHAHFHC: 1.50±0.22; P=0.007, F(1,4)=12.42).
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Plasma analysis
Moreover, as reported previously by Wielinga et al., the ARA&DHA treated mice 
showed a decreased plasma cholesterol level compared to chow fed mice (Chow: 
3.01±0.08 mM; ARA&DHA: 2.71±0.07 mM; P=0.02, F(1,43)= 5.92). Also plasma 
triglyceride concentrations were significantly decreased in the ARA&DHA fed 
mice (Chow: 2.32±0.09 mmol/L; ARA&DHA: 2.01±0.01 mmol/L; P=0.03, F(1,43)= 
5.20). Plasma insulin levels were below 0.5 ug/mL in early life and comparable in 
both groups (Insulin: Chow: 0.019±0.00 ug/mL; ARA&DHA: 0.031±0.00 ug/mL), 
whereas plasma leptin concentrations were below detectable for both diets.
At 26 weeks of life, plasma cholesterol levels remained stable in the ChowChow 
diet group up to 20 weeks, whereas the plasma cholesterol concentrations increased 
in the ChowHFHC and ARA&DHAHFHC diet group (ChowChow: 
2.92±0.08 mM; ChowHFHC: 6.23±0.01 mM; ARA&DHAHFHC: 6.45±0.12 
mM; P=0.00 F(1,28)=476,25). Plasma triglycerides concentrations decreased 
in all HFHC fed mice, compared to chow fed mice (ChowChow: 2.19±0.30 
mmol/L; ChowHFHC: 1.07±0.02 mmol/L; ARA&DHAHFHC: 1.12±0.02 
mmol/L; P=0.00, F(1,28)=184,07). Moreover, plasma insulin levels remained low 
for all diet groups (Chow/Chow: 0.63±0.06 ug/mL; ChowHFHC: 0.46±0.12 
ug/mL; ARA&DHAHFHC: 0.50±0.11 ug/mL). Leptin plasma levels increased 
in the mice fed a HFHC diet (ChowChow: 1.00±0.30 ng/mL; ChowHFHC: 
2.08±0.58 ng/mL; ARA&DHAHFHC: 3.14±0.46 ng/mL; P=0.10, F(1,28)=2,87). 
Liver, white adipose tissue and brain tissue analysis
At 26 weeks all mice were sacrificed, and organs harvested and weighed. Liver 
weight was significantly decreased in the ChowHFHC-diet group compared to 
the ChowChow-group (P<0.001, F(1,28)=32.63; Fig. 2B), whereas epididymal 
and inguinal fat weights were significantly increased in the ChowHFHC-group 
compared to the ChowChow-group (P=0.001, F(1,28)=12.97; P=0.010, 
F(1,28)=7.55; Fig. 2B). 
In order to determine whether the storage of lipids was indeed increased in 
adipocytes due to HFHC feeding, we measured the size of adipocytes in omental, 
epididymal and inguinal fat depots. In later life, mice fed a HFHC diet had an 
increased adipocyte size in all three analyzed fat depots, versus chow fed mice 
(Omental: P=0.01, F(1,28)=6,84; Epididymal: P<0.001, F(1,28)=14,88; Inguinal: 
P=0.03, F(1,28)=5,41; Fig. 2C). Only in the inguinal fat depot, the adipocyte size 
of mice fed ARA&DHA was reduced, when compared to HFHC fed mice (P=0.05, 
F(1,28)=4,27; Fig. 2C).
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In order to reveal changes in insulin and leptin metabolism in the brain, we 
performed biochemical analysis of the mice brain tissue. No significant diet effects 
were found in mRNA levels of the leptin receptors A and B nor in mRNA levels of 
preproinsulin and the insulin receptor (data not shown). 
Figure 2. Metabolic parameters. A) Body weight. In early life, the ARA&DHA-group 
(N=15) showed a reduced body weight when compared to the Chow-group (N=30). In later 
life, mice on the ARA&DHAHFHC diets had a decreased body weight compared to the 
ChowHFHC-group (N=15 per diet group). B) Organ weights at 26 weeks of life. Liver 
weight was reduced in the ChowHFHC-dietgroup. Epididymal and inguinal fat weight was 
increased in the ChowHFHC-mice (N=15 per diet group). C) Adipocyte sizes in omental, 
epididymal and inguinal fat depots. HFHC feeding induced an increase in adipocyte size in 
omental and epididymal fat depots. Early life ARA&DHA dietary intake reduced the adipocyte 
size within inguinal fat depots (N=15 per diet group). D) Representative image of histologically 
(H&E) stained fat tissue. *= P≤0.05; #=0.08.
Cerebrovascular parameters
CBF analysis
We performed ASL-measurements to indicate CBF levels in the brains of 
ApoE3*Leiden mice (Fig. 3). In early life, mice fed the ARA&DHA-diet demonstrated 
an increased vasoactivity within the cortex, compared to the mice fed a chow-diet 
(P=0.034, F(1,25)=5,04) (Fig. 3C). These results illustrate an increased ability of the 
cerebrovasculature to react on vasoconstrictive stimuli.
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Figure 3. CBF-levels and vasoactivity in early life. A) CBF-levels. B) CBF-levels under 
vasoconstrictive conditions. C) Vasoactivity. It represents the ability of the cerebrovasculature 
to react on vasoconstrictive stimuli. Mice fed ARA&DHA had an increased vasoactivity in the 
cortex. Chow: N=18; ARA&DHA: N=9; *= P≤0.05.
39
ARA&DHA counteracts obesity-related brain changes
2
In 26 week-old mice the CBF level was significantly increased in the 
ChowHFHC-diet group within the cortex (P=0.044,(F(1,14)=4,87) and thalamus 
(P=0.017, F(1,14)=7,33) compared to the ChowChow-diet group (Fig. 4A). In 
addition, a trend for increased CBF-levels of mice on ChowHFHC diets compared 
to mice on ARA&DHAHFHC-diets was found in the thalamus (P=0.074, 
F(1,17)=3,62; Fig. 4). In vasoconstrictive conditions, the ChowHFHC-group 
revealed again a significant increase in CBF levels in the cortex (P=0.009, 
F(1,14)=7,33), hippocampus (P=0.054, F(1,14)=4,43) and thalamus versus 
ChowChow (P=0.014, F(1,14)=7,86) (Fig. 4B). No significant diet effects were 
revealed on the vasoactivity at 26 weeks. 
Immunohistochemistry GLUT-1
GLUT-1 is a transporter protein for glucose located in the blood vessel wall and 
can be used to elucidate vascular integrity in the brain. GLUT-1 fluorescent 
immunohistochemistry demonstrated significant effects on the number of GLUT-1 
positive blood vessels per µm2 (Fig. 4C). The ARA&DHAHFHC fed mice showed 
an increased number of blood vessels compared to the ChowHFHC fed mice 
in the cortex (P=0.025, F(1,28)=5.64), hippocampus (P=0.019, F(1,28)=6.18) and 
thalamus (P=0.017, F(1,28)=6.45) (Fig. 4C). ChowHFHC fed mice also had less 
GLUT-1 positive blood vessels compared to the ChowChow fed mice within the 
hippocampus (P=0.078, F(1,28)=3.35) and thalamus (P=0.072, F(1,28)=3.50) (Fig. 
4C). The amount of GLUT-1 protein within the cortex, hippocampus and thalamus 
was analyzed by intensity measurements, and mRNA levels of GLUT-1 were 
analyzed using qRT-PCRs. In both measurements no significant diet effects were 
found, indicating that the GLUT-1 protein and mRNA expression within the blood 
vessel wall was unchanged by diet while number of blood vessels was changed by 
diet. In addition, we performed biochemical experiments (qRT-PCRs) to analyze 
the blood brain barrier and vasculogenesis in the brain. Occludin and vascular 
endothelial growth factor A (VEGF-A) were examined, and yet no significant diet 
effects were found (data not shown).
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Figure 4. Cerebrovascular parameters in later life.  
A) CBF-levels. ChowHFHC-diet group had an increased CBF-level within the cortex 
and thalamus. ARA&DHAHFHC fed mice demonstrated decreased CBF levels in the 
thalamus. (ChowChow: N=7; ChowHFHC: N=9; ARA&DHAHFHC: N=10) B) 
CBF-levels under vasoconstrictive conditions. ChowHFHC fed mice had increased CBF 
levels in the cortex, hippocampus and thalamus. (ChowChow: N=7; ChowHFHC: 
N=9; ARA&DHAHFHC: N=10) C) Quantification GLUT-1 immunohistochemistry in 
the cortex, thalamus and hippocampus. GLUT-1 is a transporter protein located in the blood 
vessel wall and is used as a marker for cerebrovascular integrity. ChowHFHC-group showed 
a significant decreased number of GLUT-1 positive blood vessels in the cortex, hippocampus 
and thalamus. (N=15 per diet group)  D) A representative immunofluorescent image of a 
GLUT-1 stained hippocampal section.*= P≤0.05; #≤0.08.
Cognitive parameters
Behavioral experiments
In early life, we examined locomotion, exploration, short term memory and 
sensory motor integration in the open field, ORT and rotarod tests. In none of 
these parameters a significant diet effect was revealed between mice fed the chow 
or ARA&DHA-diet. 
In later life, mice were tested in the open field and rotarod, and again no significant 
diet effects were found in locomotion, exploration and sensory motor integration. 
A long term memory test, the MWM, was performed in mice aged 25 weeks. 
During acquisition, all mice learned and found the platform location. Analyses 
of the search strategies revealed a significant diet effect (P=0.020, F(1,28)=6.30); 
the ARA&DHAHFHC fed mice used an increased level of spatial-hippocampus 
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dependent search strategies compared to the ChowHFHC fed mice (Fig. 5A). 
In the probe trial, ARA&DHAHFHC fed mice had a decreased swimming 
distance (P=0.042, F(1,28)=4.55) and velocity (P=0.038, F(1,28)=4.73) compared 
to ChowHFHC fed mice.
Figure 5. MWM learning and memory, and DTI gray matter integrity in later life. 
A) Classification of the search strategies in the MWM. ARA&DHAHFHC-group had 
an increased hippocampal dependent spatial learning-ability. Y-axis displays percentage of 
used hippocampal dependent search strategy (  percentages= more use of a hippocampal 
dependent search strategy, N=15 per diet group)  B) Mean diffusivity (MD) levels of mice aged 
26 weeks. ChowHFHC-group had increased MD levels in the hippocampus, motor cortex 
and somatosensory cortex, which indicates a decreased gray matter integrity. (ChowChow: 
N=6; ChowHFHC: N=8; ARA&DHAHFHC: N=9) *= P≤0.05; #≤0.08 AC: Auditory 
cortex; Hip: Hippocampus; MC: Motorcortex; SSC: Somatosensory cortex; VC: Visual cortex.
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DTI and rsfMRI
DTI-experiments were assessed to determine white and gray matter integrity via 
fractional anisotropy (FA) and mean diffusivity (MD) levels; no significant diet 
effects were revealed in FA or MD levels in early  life at 13 weeks. However, functional 
connectivity, assessed by rsfMRI, was increased in mice fed a ARA&DHA-diet in 
early life. These diet effects were mainly found in functional connections between 
the following brain regions: auditory, visual, motor and somatosensory cortex (Fig. 
6A-B). 
In the second set of MRI experiments at 26 weeks of life, DTI parameters, FA 
and MD levels, were again used to analyze white and gray matter integrity. No 
significant effects were found in FA-levels, while MD-levels of ChowHFHC fed 
mice were affected compared to ChowChow fed mice. More specifically, the 
ChowHFHC-diet group showed an increased MD-level within the hippocampus 
(P= 0.059, F(1,12)=4.35), motor cortex (P= 0.026, F(1,12)=4.35) and somatosensory 
cortex (P= 0.049, F(1,12)=4.82) versus only Chow fed mice (Fig. 5B). In the 
motorcortex, the MD-levels of the ChowHFHC fed mice were also significantly 
increased (P= 0.024,F(1,15)=5.80) when compared to ARA&DHAHFHC 
(Fig. 5B). Together, these results may indicate neuronal loss and decreased gray 
matter integrity in the ChowHFHC fed mice in these areas (Fig. 5B). rsfMRI 
analysis revealed a decreased functional connectivity in ChowHFHC relative to 
ChowChow. These significant diet effects were found in the connectivity between 
the ventral hippocampus, motor and somatosensory cortex (Fig.6C-D). Compared 
to the ChowHFHC fed mice, the ARA&DHAHFHC fed mice showed an 
increased functional connectivity between the ventral hippocampus, motor and 
somatosensory cortex (Fig. 6E-F). 
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Figure 6. Early and later life connectivity between brain regions using rsfMRI. 
A) Total correlation matrixes of the Chow and ARA&DHA diet group at 13 weeks of life. 
C-E) In later life at 26 weeks, the total ROI matrixes of the ChowChow, ChowHFHC 
or ARA&DHAHFHC fed mice. The selected brain regions, dorsal hippocampus (DH), 
ventral hippocampus (VH), auditory cortex (AC),motor cortex (MC), somatosensory cortex 
(SSC) and visual cortex (VC), are subdivided in left hemisphere region (first row) and right 
hemisphere region (second row). In general the DH and VH are strongly bilaterally connected, 
and AC, MC and SSC are highly interconnected. A higher Z-score (red) indicates a stronger 
functional connectivity. B-D-F) Statistical analyses of functional connectivity to reveal 
a significant diet effect are also represented as a matrix. Yellow: P<0.050 . A) In early life, 
ARA&DHA fed mice had an increased functional connectivity between the motor, visual and 
somatosensory cortex. B) Statistical matrix of Chow vs ARA&DHA in early life. (yellow= 
P<0.050) C) The ChowHFHC-group has a decreased functional connectivity between 
the ventral hippocampus, motor cortex and somatosensory cortex. D) Statistical matrix of 
ChowChow vs ChowHFHC in later life. (yellow= P<0.050) E) Functional connectivity 
was increased in ARA&DHAHFHC fed mice compared to ChowHFHC fed mice between 
the ventral hippocampus, auditory, motor and somatosensory cortex. F) Statistical matrix 
of ChowHFHC vs ARA&DHAHFHC in later life. (yellow= P<0.050) Chow: N=20; 
ARA&DHA: N=10; ChowChow: N=7; ChowHFHC: N=7; ARA&DHAHFHC: N=7.
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Discussion
In the present study, we are the first to show that a mild obesogenic HFHC diet 
influences brain structure and function by increasing CBF, decreasing gray matter 
integrity and functional connectivity. Secondly, brain structure and function 
can be preserved by an early life ARA&DHA dietary intake. Moreover, early life 
programming is important in the etiology of mild obesity. 
Early life
Fetal and neonatal time periods are critical time windows in development. Nutrition 
in these critical periods can have long-term phenotypic consequences through 
permanent structural changes in organs, which is associated with the development 
of long term obesity (233-237). Furthermore, the amount and ratio of omega-6 
and omega-3 LCPUFAs that are consumed during childhood may determine 
the adult metabolic profile and risk factors of disease (203). Failure to provide 
LCPUFAs in these critical developmental periods results in alterations in visual 
function, spatial learning and memory, nerve growth factor levels and dopamine 
production, as well as decreased glucose utilization in the brain (238-245). These 
effects could be related to, for instance, the amount of DHA incorporated in the 
neuronal membranes, because DHA can change the physicochemical properties 
of membranes, and deficiency of DHA can impair G-protein receptor-mediated 
signalling in neural membranes (238, 242, 244, 245). Furthermore, Gomez-Pinilla 
et al. showed that dietary DHA intake elevated the amount of leptin receptor b in 
the hypothalamus and hippocampus, but did not affect ghrelin receptors indicating 
that DHA specifically influences leptin signalling in the hypothalamic appetite 
system (246). Of note, the development of the hypothalamic appetite regulatory 
network occurs predominantly after birth (247). It is well established that ghrelin 
affects the orexigenic Neuropeptide Y (NPY) and Agouti-related peptide (AgRP) 
neurons in the arcuate nucleus of the hypothalamus resulting in an increased 
appetite (248, 249). In contrast, leptin inhibits the NPY and AgRP neurons and 
activates the anorexigenic neurons of the melanocortin (α-MSH)/cocaine and 
amphetamine-regulated transcript (CART) pathways in the arcuate nucleus, which 
results in decreased food intake and increased energy expenditure (248). ARA 
metabolites can modulate hypothalamic corticotropin-releasing hormone secretion, 
and induce a long-term activity-dependent enhancement of synaptic transmission 
in the hippocampus (16, 250). Thus, the hypothalamus works in concert with the 
hippocampus to regulate energy homeostasis, food intake and cognitive function 
(251-253). Treatment with ARA and DHA in early life may affect one or several of 
these key regulatory processes of metabolic homeostasis, and may involve effects in 
hypothalamus and hippocampus. The observed effects suggests that LCPUFAs like 
ARA and DHA exhibit promising effects in the prevention and treatment of obesity 
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and the metabolic profile, possibly via effects on the hypothalamic appetite system, 
already in early life.
Metabolism
In early life, ApoE3*Leiden mice fed LCPUFAs gained significantly less weight, and 
plasma cholesterol and triglycerides levels were decreased. These mice still had a 
lower body weight after 3 months of HFHC diet feeding, despite increased plasma 
cholesterol and leptin levels. In later life, we observed in all HFHC treated mice a 
decreased liver weight, while inguinal and epididymal fat weight increased. These 
results indicate a changed lipid storage in the HFHC-fed mice, with lipids possibly 
being stored into the epididymal and inguinal fat tissue instead of in the liver (254). 
Some studies reported an increased liver weight in mice after high fat and /or high 
carbohydrate feeding (210, 255), and most of them described an increased fat 
accumulation in the hepatic cells in the context of NAFLD (256-258). Although, 
West et al. found that an obesity inducing diet did not significantly increase the 
liver weight in nine inbred mice strains (259). In contrast, in our current study we 
found a decreased liver weight in later life. This effect appeared not to be related 
to ARA&DHA treatment. The observed reduction in liver weight upon switching 
from chow diet to a fat-containing obesogenic diet may be related to an effect on 
de novo lipogenesis in combination with a preferred storage of fat in white adipose 
tissue during obesogenic diet feeding. Under chow conditions energy comes mainly 
from carbohydrates and only in little amounts from dietary fat. Therefore, de novo 
lipogenesis is active to produce the fatty acids that are needed for organ function 
(e.g. heart). When animals are switched to obesogenic diets containing more 
dietary fat, de novo lipogenesis is reduced in the liver, and fat storage processes are 
activated in adipose tissue (206, 260). In parallel, under high fat diet conditions, 
fat storage in white adipose tissue is activated and, associated with this, liver fat 
and mass decline as storage pools in adipose tissue are filled. Indeed, we observe 
an increase in epidydimal WAT tissue after the switch from chow to high fat diets. 
Of note, under more extreme conditions these initially physiological responses 
may develop into more pathophysiological responses in liver and adipose tissue, 
ultimately leading to adipose tissue hypertrophy and inflammation and associated 
hepatic steatosis with increased liver weights as shown recently in longitudinal 
studies of diet-induced obesity, adipose tissue inflammation and NAFLD (260, 
261). ARA&DHA fed mice displayed reduced adipocyte size within the inguinal 
fat depot. In agreement, Wielinga et al. reported that inguinal adipocyte cells were 
smaller in ApoE*3Leiden mice with early life ARA&DHA intake after eight weeks 
of HFHC feeding (202). It is hypothesized that a reduced adipocyte size due to 
early ARA&DHA supplementation could be a result of variations in adipocyte 
differentiation, as expression profiling revealed significant differences in expression 
of hundreds of genes between different adipose depots in rodents (262). These 
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findings confirm that ARA&DHA dietary intake in early life strengthens the ability 
to cope with a mild obesogenic diet later in life.
Cerebrovasculature
LCPUFA intake improved the vasoactivity in the brains of ApoE3*Leiden mice 
in early life. In monkeys, a PET study revealed that DHA-supplementation for 
one week period resulted in a significantly increased regional CBF response to 
stimulation (263). Ellis et al. found in rabbits that ARA induced a dose-dependent 
blood vessels dilation response of which the maximum was 100%. DHA itself had 
no effect on vessel diameter, but reduced the dilation produced by ARA (19). It 
may be hypothesized that intake of combined ARA and DHA could neutralize the 
cerebrovascular reactivity.
It is well known that obese or overweight patients have a reduced CBF (18, 264-266). 
In the current study however, HFHC-diet feeding increased CBF levels, but not the 
vasoactivity in later life. Moreover, HFHC diet was found to decrease the number 
blood vessels in the cortex, thalamus and hippocampus, which indicates that a 
HFHC diet is able to affect cerebrovascular integrity. Other studies revealed that 
exposure to a high fat diet could induce cerebrovascular remodeling (267-269). 
It should be taken into account that the blood vessel walls in the relatively mild 
ApoE3*Leiden obese mouse model are not severely damaged yet and may still 
be able to adapt to the HFHC induced changes. To elucidate these findings, 
future research should focus on the role of LCPUFAs in endothelial function, 
atherosclerotic plaque development and blood pressure in mildly obese and more 
pronounced obese rodent models in critical periods of development. Overall, 
we demonstrated that a HFHC-diet provokes adaptations in the cerebrovascular 
integrity and CBF. Furthermore, dietary ARA&DHA intake in early life is able to 
counteract these adaptations.
Cognition, brain structure and function
We did not find ARA&DHA effects on cognition after eight weeks of dietary intake. 
In line with this, no significant differences were found by Lim et al. in the results 
of the maze-learning tests between Crj:CD-1 mice fed DHA diets for a period of 
one or two weeks (270). However, after a 12 week period of DHA-supplementation, 
mice required less time to reach the maze exit and strayed into blind alleys fewer 
times (270). These results suggest that it may take time before learning abilities 
improve after the incorporation of DHA into the neuronal membranes (270). 
Mice fed an ARA&DHA-diet showed an increased functional connectivity. In line 
with our findings, a study of Grayson et al. demonstrated that cortical modular 
organization in monkeys supplemented with DHA resembled a healthy human 
brain (271). Furthermore, individuals with low levels of dietary LCPUFAs had 
decreased functional connectivity within the early visual pathway and throughout 
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higher-order associative cortex and showed impairment of distributed cortical 
networks (271). These findings emphasize that LCPUFAs modulate brain structure, 
i.e. functional connectivity. 
The ARA&DHA fed mice used a more specific, advanced, and hippocampal 
dependent cognitive search strategy later in life. This finding implies that dietary 
ARA&DHA intake can improve hippocampal function. Short exposure to a high 
fat and sucrose diet has been shown to impair hippocampal dependent place 
recognition, but not the object recognition (272, 273). HFD exposure in rats 
impaired long-term spatial reference memory in the Morris water maze, without 
affecting acquisition or short-term memory (274). Accordingly, LCPUFAs and 
high fat diets seem to specifically modulate spatial memory. 
We revealed an increased structural loss of gray matter in later life due to HFHC 
exposure. Moreover, ARA&DHA dietary intake protected against neuronal loss. 
Human studies revealed that obese children had significant regional gray matter 
reduction in middle temporal gyrus, thalami, pre and postcentral gyrus, and 
cerebellum (92, 275). DHA plays a crucial role in maintaining cortical neuronal 
integrity (276). In healthy subjects supplementation with DHA, EPA and vitamin E 
significantly attenuated gray matter volume loss in the hippocampus and temporal 
brain regions (277). These findings emphasize the ability of a HFHC diet and 
LCPUFAs to affect gray matter structure and volume. Kullman et al. reported that 
obese individuals showed a decreased functional connectivity strength in the left 
insular cortex (278). The insular cortex is considered to be the primary gustatory 
cortex (279), as it represents an important relay of the neural circuitry, essential in 
food intake, connecting the hypothalamus, orbitofrontal cortex and limbic system. 
We showed that functional connectivity was reduced in mice fed HFHC-diet, 
especially within the hippocampus, motor, and somatosensory cortex. These 
findings indicate that a HFHC-diet induces impairments within the gray matter 
neuronal structure and functional connectivity in specific brain regions. Dietary 
ARA&DHA intake in early life is able to counteract these HFHC diet-induced 
detrimental effects on brain structure and function in later life. 
The study further emphasizes the importance of LCPUFAs as dietary components 
to counteract detrimental effects related to overweight and obesity, and that early 
life LCPUFAs support cognitive flexibility during later life challenges. Sensitive 
imaging techniques are essential to investigate and demonstrate the subtle 
detrimental adaptations induced by a HFHC diet in a mildly obese rodent model. 
Future research should focus on interactions of dietary components, optimal 
supplementation period and the vulnerability within different periods of life.
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Abstract 
Midlife obesity affects cognition and increases risk of developing dementia. Recent 
data suggest that intake of the short chain fatty acid butyrate could improve memory 
function, and may protect against diet-induced obesity by reducing bodyweight 
and adiposity. 
We examined the impact of a high fat diet (HFD) followed by intervention with 5% 
(w/w) dietary butyrate on metabolism, microbiota, brain function and structure 
in the low-density-lipoprotein receptor knockout (LDLr-/-) mouse model in mid- 
and late life. 
In mid-adult mice, 15 weeks of HFD induced adiposity, liver fibrosis and 
neuroinflammation, increased systolic blood pressure and decreased cerebral blood 
flow, and functional connectivity assessed with neuroimaging. The subsequent two 
months butyrate intervention restored these detrimental effects to chow fed control 
levels. Both HFD and butyrate intervention decreased variance in fecal microbiota 
composition. In late adult mice, HFD showed similar detrimental effects and 
decreased cerebral white and gray matter integrity, whereas butyrate intervention 
attenuated only metabolic parameters. 
HFD induces detrimental effects in mid- and late adult mice, which can be 
attenuated by butyrate intervention. These findings are consistent with reported 
associations between midlife obesity and cognitive impairment and dementia in 
humans. We suggest that butyrate may have potential in prevention and treatment 
of midlife obesity.
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Introduction
Obesity-related diseases are becoming one of the major health-care problems of 
the twenty-first century (1). Obesity is associated with structural brain changes, 
cognitive impairment and neurodegenerative diseases, besides the well-known 
metabolic complications (2, 3). Particularly in midlife, it has been reported 
that obesity can affect cognitive functioning and increase the risk of developing 
dementia (3). It has been hypothesized that obesity may exaggerate aging processes 
(280). Multiple rodent studies provided indications for adverse effects of obesity on 
cognitive functioning in aged mice (281, 282). Therefore, novel approaches related 
to weight management in aging are urgently required.
The potency of short chain fatty acids such as butyrate has been demonstrated in 
treatment of obesity and obesity related disease conditions in recent animal studies 
(20). Butyrate is a natural product of bacterial fermentation of mainly undigested 
plant polysaccharides and resistant starch in the colon. It has anti-inflammatory 
properties and is involved in the regulation of liver lipogenesis, adipocyte 
differentiation and energy intake (23). In addition, butyrate is associated with 
associative learning and memory functions in severe Alzheimer’s disease mouse 
models via mediating histone acetylation (283). Obese humans have a decreased 
concentration of butyrate-producing bacteria (24).
In this study, we evaluated the effect of butyrate on microbiota, brain structure 
and function, and key metabolic organs in context of high fat diet (HFD)-induced 
obesity. LDLr-/-Leiden (LDLr-/-) mice were assessed in vivo and ex vivo experiments 
in two age groups, mid- (3-6 months old (m.o.)) and late (6-12 m.o.) adult mice. 
The LDLr-/- Leiden mouse model was chosen for this study because of its high 
sensitivity to develop obesity and obesity-associated metabolic and vascular 
complications in multiple organs when fed HFD with 45% fat content (190, 191, 
284, 285), and subsequently we think these complications can detrimentally affect 
brain function. Our results provide evidence that butyrate can attenuate HFD 
induced impairment during mid- and late adulthood, whereas HFD induced 
alternations in brain function can only be restored in mid-adulthood. Overall, this 
study elucidates the effect of diet in the maintenance of metabolic and cognitive 
flexibility during life.
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Materials and Methods
Animals and diets
Male LDLr-/- Leiden mice originated from the SPF breeding stock at TNO 
(TNO Metabolic Health Research, Leiden, the Netherlands), and were housed 
in individually ventilated cages in conventional animal rooms in the preclinical 
imaging centre (PRIME) at the central animal laboratory, Radboudumc Nijmegen, 
the Netherlands (ad libitum access to acidified tap water and food; relative humidity 
50–60%, temperature 21°C, light cycle 7 a.m.–7 p.m. and a maximum of 5 mice 
per cage). The animal experiments were approved by an independent institutional 
ethical committee on animal care and experimentation (Zeist, The Netherlands), 
approval number DEC3682 containing a statistical power analysis to minimize the 
number of animals. This study is performed and reported according to ARRIVE 
guidelines (286).
To examine age differences, we assessed a cohort of 30 LDLr-/- mice of three 
m.o. and a second cohort of six m.o. mice representing mid- and late adulthood, 
respectively. Both cohorts consisted of three diet groups: Chow (33.0% kcal protein, 
58.0% carbohydrates and 9.0% kcal fat, Sniff R/M-H diet V1530, Sniff Spezialdiäten 
GmbH, Soest, Germany), HFD (20.0% kcal protein, 35.0% carbohydrates and 
45.0% kcal fat, D12451, Research Diets Inc, New Brunswick, USA) and HFD 
enriched with 5% (w/w) butyrate (HFDB). The dietary compositions are presented 
in supplementary Table 1. The first cohort, representing mid-adulthood, consisted 
of a group receiving a standardized chow diet from birth until the end of the study, 
a second group received a HFD at three months of age and a third group switched 
to a HFD after three months as well, and at seven m.o. the HFD was enriched with 
butyrate for two months (Fig. 1A). The second cohort representing late adulthood 
was subdivided in the same manner, only switched to a HFD at six m.o. and received 
at ten m.o. a butyrate intervention (Fig. 1B). Mice were examined for diet-induced 
changes in microbiome, metabolism, cognition, brain structure and function (Fig. 
1). 
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Figure 1. Study design. A) Mid-adulthood, high fat diet (HFD) feeding started at 3 months of 
age and when 7 m.o. the butyrate intervention started (HFD enriched with butyrate (HFDB)). 
Cognitive and MRI experiments were performed at 9 months of age. B) Late adulthood, 
exposure of the HFD started at 6 m.o., and at 10 months of age the butyrate intervention 
started. Late adult mice were assessed in the cognitive and MRI experiments at 12 months of 
age. Individual body weight and food intake (at cage level) were monitored over time. Blood 
samples were taken after 5 hours of fasting (8 a.m.–1 p.m.). At the end of the experiment, all 
mice were anesthetized and sacrificed by transcardial perfusion with 0.1M phosphate-buffered 
saline (PBS). Thereafter organs were harvested and used for immunohisto- and biochemical 
experiments. MB= collect faeces for microbiome analyses; BL= blood sample collection. 
MWM= assessed in Morris water maze; BP=blood pressure measurements; MRI= examined 
with magnetic resonance imaging for resting state fMRI (rsfMRI), arterial spin labelling (ASL) 
and diffusion tensor imaging (DTI). HFD=high fat diet; HFDB=high fat diet enriched with 
butyrate; m.o.=months old; n= group size.
Plasma analyses
Total plasma cholesterol, insulin and triglyceride levels were measured using 
standardized ELISA kits (202). Glucose levels were assessed using the OneTouch 
Ultra glucometer (Lifescan Benelux, Beerse, Belgium).
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Fecal sample collection and DNA extraction
Fecal samples were collected at the end of the study and frozen immediately at 
−80°C. Samples were mechanically homogenized and genomic DNA was isolated 
using the AGOWA mag Mini kit (DNA Isolation Kit, AGOWA, Berlin, Germany) 
according to the manufacturer’s instructions.
Metagenomic sequencing
A fragment of the 16S rRNA gene (~270 bp), spanning the V4 hypervariable regions, 
was PCR amplified using F515/R806 primers within 30 cycles (287). Purified PCR 
products were paired-end sequenced on the Illumina MiSeq platform (Illumina, 
Eindhoven, The Netherlands). The sequence data was processed with Mothur 
v.1.33.2 (288) and grouped using Minimum Entropy Decomposition (MED) 
algorithm that clusters 16S rRNA gene amplicons in a sensitive manner (289). 
Sequences were taxonomically classified by the RDP-II Naive Bayesian Classifier 
using a 60% confidence threshold. Community profiles were compared by Bray–
Curtis dissimilarity and Weighted Unifrac clustering of MED abundance (290). 
Sequences were normalized to 10000 sequences per samples. Population-level 
comparison of MED abundance between samples collected was performed using 
the Metastats tool (291).
Morris water maze 
The Morris water maze (MWM) was assessed to examine long term memory and 
spatial learning abilities. We performed and analyzed the MWM according to 
standardized protocols previously described (292).
Blood pressure measurements
A computerized and warmed tail-cuff plethysmography device was used to measure 
systolic blood pressure (SBP; IITC Life Scientific Instruments, Woodland Hill, 
CA). The mice were habituated to the restrainer and acclimatized to the complete 
procedure. Six SBP-measurements per trained mouse were averaged to obtain the 
mean SBP.
MRI-experiments
MRI measurements were performed with a 11.7 T Biospec Avance III small 
animal MR system (Bruker BioSpin, Ettlingen, Germany) which operated with 
a Paravision 6.0 software platform. Isoflurane (Nicholas Primal (I) Ltd, London, 
United Kingdom) was used for anaesthesia (3.5% for induction for 2 minutes and 
approximately 1.8% for maintenance in a mixture of oxygen and medical air (1:2)). 
We used standardized protocols for these MRI measurements published by Zerbi 
et al. (226), and we assessed functional connectivity (FC) (resting state fMRI), 
regional cerebral blood flow (arterial spin labeling (ASL)) and gray and white matter 
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integrity (diffusion tensor imaging (DTI)). Imaging parameters are represented in 
supplementary table 2. Mice were excluded from further MRI analysis in case of 
positioning artefacts. 
(Immuno)histochemistry
Mice were sacrificed via transcardial perfusion with 0.1 M phosphate-buffered 
saline (PBS), and organs harvested e.g. brain, liver and fat depots. Organs used 
in (immuno)histochemical experiments were post-fixed in 4% paraformaldehyde 
for 24 hours. 5 μm thick paraffin-embedded cross-sections of liver tissue were 
stained with hematoxylin and eosin. NAFLD was scored blinded using a general 
scoring system for rodent models according to an established protocol (293). 
Ionized calcium binding adapter molecule-1 (IBA-1) antibody was used to detect 
activated microglia (goat anti-IBA-1 (1:2500; Abcam, ab5076)) as indicator for 
neuroinflammation in 30-µm thick coronal brain sections. We used a previously 
described standardized protocol for immunohistochemistry and its quantification 
(213). 
Quantitative real-time polymerase chain reaction
The snap-frozen dissected hippocampus of the right hemisphere was used 
for the analysis of mRNA levels using quatitative real-time polymerase chain 
reaction (qRT-PCR) in duplo according to a previously described protocol (213). 
Forward and reverse primer sequences are represented in supplementary table 3. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a reference gene serving 
as a control for general cell activity. 
Statistical analysis
A random and double-blind selection procedure was used throughout the 
experiment. The results are expressed as means ± standard error of mean (SEM). 
Means were analyzed using repeated measures or multivariate analysis of variance 
(ANOVAs) with Bonferroni correction for multiple testing in, SPSS20 (IBM SPSS 
Statistics 20, IBM Corporation, Armonk, New York, USA). Microbiota correlation 
analyses were performed using Pearson correlations. Supplementary table 4 
provides the P and F values of the found significant effects. 
Results
Butyrate restored HFD induced metabolic adaptations in mid- and late adult 
mice
In the mid-adult cohort (9 m.o.), body weight of the HFD mice increased over 
time and was 30% higher (P<0.001) compared to Chow mice at the end of the 
experiment. A two months butyrate intervention in mid-adult mice on HFD did 
not significantly reduce bodyweight of the HFD fed mice (16%; P=0.11). However, 
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a two months butyrate intervention in late adult mice on HFD resulted in a body 
weight loss of 23% (P<0.001) compared to HFD fed mice. In this late adult cohort 
(12 m.o.), body weight of the HFD fed mice was 35% higher (P<0.001) compared 
to chow fed mice. (Fig. 2 and Supplementary table 4). Food intake was monitored 
per cage (n=2 or 3) in grams, and subsequent calculated into kilo calorie intake per 
day per mouse. No significant differences were found between the three dietary 
interventions in intake (kcal) over time indicating that the energy intake was the 
same for all diet groups (Fig. 2 and Supplementary table 4).
A HFD increased the cholesterol and triglycerides plasma levels in mid- and late 
adult mice compared to Chow. The subsequent butyrate intervention lowered the 
plasma levels of cholesterol and triglycerides in both mid- and late adult mice. No 
diet effects were found in glucose plasma levels in age cohorts. In mid-adulthood, 
plasma insulin levels were slightly increased by HFD. Butyrate intervention 
restored insulin levels compared to solely a HFD which were even below Chow 
insulin levels, which was more pronounced in late adulthood.
Liver, epididymal, inguinal and omental fat depots was weighed after sacrifice. Liver 
weight, omental and inguinal fat depot weight were increased in HFD fed mice 
both at age cohorts compared to chow fed mice. Subsequent butyrate intervention 
restored these metabolic adaptations (Supplementary table 4). 
Butyrate recovered hepatic steatosis induced by HFD feeding in mid- and late 
adult mice
A HFD increased the NAFLD as hepatic steatosis and hypertrophy were increased 
in mid- and late adult mice. In late adult mice a HFD increased the percentage of 
fibrosis. A butyrate intervention restored these observed changes in the liver as it 
decreased hypertrophy, fibrosis and macrovesicular steatosis (Fig.2). In addition, 
inflammatory aggregates in the liver were increased in late adult mice fed a HFD 
(Supplementary Fig. 1).
Butyrate restored HFD induced spatial memory impairment in mid-adult 
obesogenic mice 
Long term memory and spatial learning were assessed in the MWM. In 
mid-adulthood, HFDB mice had a shorter latency to reach the platform than HFD 
mice (Supplementary Fig. 2A). In the first 30 seconds of the probe trial, mid-adult 
HFD mice were in the former platform NE-quadrant for a shorter time period, 
compared to HFDB mice (Supplementary Fig. 2C), indicating a diminished spatial 
memory. The swim paths of all mice were classified to assess the degree of used 
hippocampus dependent search strategies. Mid-adult mice fed HFD showed 
less hippocampus-dependent search strategies than mid-adult mice fed chow 
(Supplementary Fig. 2D). In late adulthood, none of these parameters (acquisition, 
probe NE duration and search strategy) revealed a significant diet effect indicating 
that diets are no longer effective in late adulthood concerning spatial memory.
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Figure 2. Body weight, calorie intake and liver tissue analysis. A) Body weight in mid adult 
(9 m.o.) mice at a HFD. A HFD enriched with butyrate (HFDB) started at 7 months of age. 
B) Body weight in late adult mice ( 12 m.o.). HFDB started at 9 months of age. C) Calorie 
intake in mid-adulthood. D) Calorie intake in late adulthood. E) Percentage of microvesicular 
steatosis. F) Percentage of macrovesicular steatosis. G) Percentage of hypertrophy of hepatic 
cells. H) Percentage of fibrosis within liver tissue. 9 m.o.= mid-adult. 12 m.o.= late adult. Data 
are presented as mean ± SEM. *P<0.050.
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Butyrate restored HFD induced SBP and CBF in mid-adulthood
LDLr-/- mice had an increased SBP between 120-150 mmHg whereas a normal 
SBP-range of an adult mouse is around 80-100 mmHg (294). Mid-adult mice fed a 
HFD had an increased SBP compared to chow fed mice (Fig. 3A). Mid-adult HFD 
mice had a decreased CBF within the hippocampus and thalamus, compared to 
both Chow and HFDB mice. Butyrate intervention restored the CBF to control 
levels in the hippocampus and thalamus (Fig. 3C-D). 
Figure 3. Systolic blood pressure and cerebral blood flow in the cortex, hippocampus and 
thalamus (A-D). A) Mean systolic blood pressure (SBP) in mmHg in mid- (9 m.o.) and late 
(12 m.o.) adult LDLr-/- mice. Six measurements were used to calculate the mean SBP per 
mouse. B, C, D) Mean cerebral blood flow (CBF) right and left cortex (B), hippocampus (C) 
and thalamus (D) in mL/100 g tissue/min. Data are presented in mean ± SEM. *P<0.050. 
Butyrate restored functional connectivity in mid-adult HFD fed mice
Mid-adult HFD mice had a decreased FC within the somatosensory cortex and 
hippocampus compared to Chow mice (Fig. 4A-C). Butyrate intervention was able 
to restore impairments in FC induced by HFD feeding in mid-adult mice (Fig. 
4D-F). FC results of late-adult mice are represented in supplementary figure 3. DTI 
was assessed to indicate diet effects on gray and white matter integrity. No diet 
effects were found in the mid-adult mice, whereas late adult mice showed a reduced 
white and gray matter integrity (Supplementary Fig. 4).
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Figure 4. resting state fMRI (rsfMRI) of mid-adult mice (9 m.o.). A, B, D and E) Total 
correlation matrixes of the Chow (A), HFD (B & D) and HFDB (E) diet group of mid-adult 
mice (9 m.o.). The selected brain regions (dorsal hippocampus (DH), ventral hippocampus 
(VH), auditory cortex (AC), motor cortex (MC), somatosensory cortex (SSC) and visual cortex 
(VC)) are subdivided in left hemisphere region (first row) and right hemisphere region (second 
row). In general the DH and VH are strongly bilaterally connected, and AC, MC and SSC 
are highly interconnected. A higher Z-score (red) indicates a stronger functional connectivity 
(FC). C & F) Statistical analyses of FC to reveal a significant diet effect, which are represented 
as a matrix. Yellow: P<0.050. More specifically, mid-adult mice on HFD showed reduced FC 
within the somatosensory cortex and hippocampus when compared to mice on Chow diet 
(A-C). In addition, butyrate intervention was able to restore the loss of FC mainly within the 
hippocampus and somatosensory cortex in mid-adult mice (D-F). Chow, n=10; HFD, n=10 
and HFDB, n=9.
Butyrate decreased neuroinflammation in mid-adult HFD fed mice 
IBA-1 immunohistochemistry indicated the level of activated microglia as measure 
of neuroinflammation. In the hippocampus and thalamus, the number of activated 
microglia was increased in mid-adult HFD mice compared to the chow fed mice 
(Fig. 5E-G). A butyrate intervention was able to decrease the number of activated 
microglia in the total hippocampus, cornu ammonis 1 (CA1) and thalamus (Fig. 
5E-G). qRT-PCRs for tumor necrosis factor-α, interleukin-6 and -1β to analyze 
inflammatory levels in the hippocampus revealed no significant effects. We 
analyzed mRNA levels of synaptic markers: synaptophysin and postsynaptic density 
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protein-95 (PSD-95). In the hippocampus of mid-adult mice synaptophysin mRNA 
levels were higher in HFD than in chow and HFDB fed mice. No diet effects were 
found for PSD95 mRNA levels (Supplementary table 4 and Fig. 5). 
Figure 5. Quantification of activated microglia as visualized by IBA-1 immunhistochemistry 
(E-H). E-G) Number of activated microglia within the hippocampus, cornu ammonis 1 
(CA1) and thalamus in mid- (9 m.o.) and late (12 m.o.) adult mice. H) Visualization (late 
adult HFDB) of IBA-1 immunohistochemistry, positive for activated microglia, within the 
hippocampus at 5x and 40x magnification. Data are presented as mean ± SEM. *P<0.050.
HFD caused shifts in gut microbiota composition
We observed dramatic differences in microbiota at genus level between chow 
and HFD fed mice based on Bray-Curtis dissimilarity index regardless of age 
(Supplementary Fig. 6A). Butyrate intervention in both mid- as well as late adult 
mice resulted in distinct changes in microbiota composition (Supplementary Fig. 
6B-C).
Butyrate-related changes in microbiota are associated with liver fibrosis and 
neuroinflammation 
Pearson correlation analyses were used to identify a possible correlation of key 
pathological features (i.e. liver fibrosis in late adult mice and neuroinflammation 
in mid-adult mice) with the observed changes in fecal microbiota. Twelve bacterial 
genera showed significant correlation with liver fibrosis (Corr. c oefficient cut-off 
0.4; P<0.05; Fig. 6A-C). The abundance of Clostridium Sensu Stricto (R=0.59; 
P=0.003), Bifidobacterium (R=0.57; P=0.005) and Enterorhabdus (R=0.56; P=0.006) 
showed a positive correlation while Clostridium XIVb (R=-0.50; P=0.01) showed a 
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negative correlation with liver fibrosis. Thirteen bacterial genera showed significant 
correlation with neuroinflammation (Corr. coefficient cut-off 0.4; P<0.05; Fig. 
6D-F). The abundance of Dorea (R=0.70; P<0.001), Clostridium IV (R=0.55; 
P=0.007) showed a positive correlation while Clostridium Sensu Stricto (R=0.-58; 
P=0.003) showed a negative correlation with neuroinflammation.
Figure 6. Fecal microbiota changes associated with liver fibrosis and neuroinflammation. 
A) Pearson correlation analysis was performed between fecal microbiota at the genus level 
and pathological liver fibrosis in late adult mice. B-C) examples of two bacterial genera that 
are correlated with liver fibrosis. D) Pearson correlation analysis was performed between fecal 
microbiota at the genus level and level of neuroinflammation in mid-adult mice. E-F) examples 
of two bacterial genera that are correlated with neuroinflammation. Data are presented in 
mean ± SEM. *P<0.05.
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Discussion
In this study, we demonstrated that butyrate intervention is able to restore HFD 
induced changes in body weight, adiposity, liver pathology, cerebral blood flow, 
functional connectivity and neuroinflammation in mid-adulthood. In late 
adulthood, both HFD and butyrate did not affect brain function, which could be 
caused by irreversible aging processes in late adulthood e.g. in the vasculature.
HFD feeding increased adiposity and body weight in LDLr-/- mice in this study, 
and these findings are repeatedly confirmed in rodent research (21, 295, 296). A 
butyrate intervention of two months restored these changes, and likewise others 
found that butyrate is able to reduce adiposity and body weight in obese mice (21, 
22). Others found an increased activity in butyrate fed mice at night (21). We did 
not observe an increased activity in butyrate fed mice, like distanced swum or 
walked in respectively the MWM or open field test (results not shown) during day 
time, and unfortunately we did not examine night-time activity. Butyrate is thought 
to be involved in lipid metabolism by regulating and slowing down intestinal fat 
transport (297). Understanding of the molecular mechanism is still incomplete, but 
short chain fatty acids (SCFAs), like butyrate, can contribute to fatty acid oxidation 
in multiple tissues and decrease fat storage in white adipose tissue as butyrate can 
induce a switch from lipid synthesis to utilization (298). Typically, this metabolic 
adjustment involves a downregulation of processes orchestrated by the peroxisome 
profilerator-activated receptor-g (PPARg) (299). An intake of butyrate affects the 
metabolic adaptations to obesogenic diet feeding via its stimulating effects on fatty 
acid oxidation and utilization. In future research physical activity levels and energy 
expenditure of these mice should be measured during day and night.
Obesity and non-alcoholic fatty liver disease (NAFLD) are marked by a state of 
inflammation initiated by HFD feeding (17). Moreover, average liver weight 
increased after HFD feeding in rats, and fat and cholesterol content in the liver was 
four to five times higher as the liver serves an alternative depot for free fatty acids 
(24). In mid- and late adult mice the liver weight, hepatic steatosis and hypertrophy 
was increased after six months of HFD feeding, and a butyrate intervention of two 
months was able to reverse these processes. A HFD induces a metabolic overload 
and thereby the metabolic pressure on the liver, resulting in alternative fat storage 
and NAFLD, whereas a butyrate intervention can restore metabolic pressure and 
adaptations.
An obesity-inducing diet diminishes hippocampal dependent search strategies and 
can generate cognitive deficits in rats (296). Reduced expression of synaptic proteins 
are suggested to be an underlying mechanism for this cognitive dysfunction (296). 
We found an increase in mRNA levels of the presynaptic marker synaptophysin 
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in mice on HFD, suggesting a possible mechanism to compensate a shortage 
of synaptophysin protein, and maybe the formation of presynapses. Butyrate 
intervention improved the spatial learning and memory performance in the Morris 
water maze, and preserved presynaptic synaptophysin mRNA levels. It has been 
reported that butyrate administration improved associative memory and learning 
function (283, 300). Butyrate most likely affects cognitive function via enhancing 
histone acetylation by inhibiting histone deacetylase (HDAC) (283). Dynamic 
changes in histone acetylation have been linked to the genetic programming 
required for memory formation (283). For instance, sodium butyrate is a HDAC 
inhibitor and adaptations in histone acetylation lead to neuroprotective and 
neuroregenerative changes in animal models for neurodegenerative diseases (283, 
300). 
Obesity and in particular central obesity, has been consistently associated with 
hypertension in humans (301). In rodents, the SBP increased after 6 months on 
high fat and high sucrose diet in an obese mouse model (302). We found that a HFD 
increased the SBP in mid-adult LDLr-/- mice. An LDLr-/- mouse model is prone to 
develop narrowed blood vessels, arterial stiffness, atherosclerosis and hypertension 
especially when fed a HFD, because oxidized LDL particles accumulate in the 
intima layer of arteries (303). Late adult mice had a high SBP, independent of diet, 
suggesting that aging processes result in structural changes within the vasculature 
and reaching a maximum in SBP. 
To this date, little research has been performed using neuroimaging on brain regions 
of the LDLr-/- mouse model. We gained novel insights using translational MRI 
techniques. Firstly, we revealed that cerebral blood flow (CBF) is decreased by a HFD 
in mid-adult LDLr-/- mice. In humans it is well established that overweight and 
obese individuals often have a decreased CBF, gray and white matter volumes (18, 89, 
90). Secondly, we have demonstrated that a HFD decreases functional connectivity 
(FC) between the somatosensory cortex and hippocampus in mid-adult mice. We 
assume that the adaptations in CBF and FC could be provoked by arterial wall 
stiffening, increased blood pressure and the development of hypertension induced 
by HFD. It can affect the cerebrovasculature and modify CBF and via blood oxygen 
level-dependent (BOLD) signaling it may affect the FC. Butyrate neutralized the 
changes in CBF and improved the impaired FC induced by a HFD. Butyrate is 
defined as a classic anti-angiogenic agent, however in low concentrations it can 
stimulate angiogenesis (304) and thereby affect BOLD signaling. In late adult mice, 
we found no HFD effects on SBP, CBF, FC and spatial memory. An exact mechanism 
for this phenomenon is unknown, although it is possible that the vascular vessels 
and capillaries may already have reached a pronounced dysfunctional state due 
to aging that cannot be further aggravated by HFD. It is known that old LDLr-/- 
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mice on chow diet develop aortic plaques and atherosclerosis only due to aging 
(305). Moreover, the rate of development of atherosclerosis is more rapid between 
10 and 14 months old LDLr-/- mice compared to older and younger LDLr-/- mice 
(306). Plasma cholesterol levels and vascular cell adhesion molecule 1 (VCAM-1) 
are possible contributors as their expression increases with age (306). We suggest 
that these aging processes induce a maximum, stationary, detrimental state within 
the vasculature. Furthermore this detrimental state cannot be further deteriorated 
by HFD nor improved by the dietary butyrate intervention tested herein. Mid-adult 
mice which have not reached this detrimental, potentially irreversible, state yet and 
may therefore be responsive to HFD as well as dietary intervention. 
During mid-adulthood, HFD induced neuroinflammation within the thalamus 
and hippocampus. In line with this, a HFD increased the activation of microglia 
and inflammatory processes (295, 307). A butyrate intervention attenuated the 
inflammatory processes by decreasing the number of activated microglia within the 
thalamus, cortex and hippocampus, which confirmed earlier findings in literature 
(308). Butyrate has anti-inflammatory properties, and in more detail, butyrate 
activates free fatty acid receptor 3 (FFAR3) and 2 (FFAR2) (309-311) and therefore 
provide a link between butyrate and the central nervous system (CNS). 
Analysis of the gut microbiome revealed pronounced changes in composition 
upon HFD feeding. These HFD induced changes were very consistent with 
observations made by others (312). The pronounced difference between chow 
and HFD composition made it difficult to discriminate the specific effects of 
butyrate from those of HFD on the microbiome. In line with observations made 
in obese humans which exhibit decreased levels of butyrate-producing bacteria 
compared to lean individuals (24), we found HFD induced in Clostridium 
XIVa abundancy. In an attempt to link the changes in microbiota with relevant 
pathophysiological endpoints, we tested whether specific genera were correlated to 
liver fibrosis and neuroinflammation. We observed a positive correlation between 
neuroinflammation and bacteria abundance of the genus clostridia (e.g. Dorea, 
Clostridium IV, Lachnospiraceae, Lachnospiraceae incertae sedis, and Clostridium 
XIVa) in fecal microbiota of mid-adult mice. A decreased abundance of these 
bacteria in HFDB fed mice correlated with a reduction in neuroinflammation as 
compared to HFD fed mice. Bacteria from the clostridia genus are known to be 
butyrate producing bacteria and are very abundant in the human colon (313). Our 
data suggest that dietary supplementation of butyrate in mid-adult mice could affect 
neuroinflammation despite a reduction of butyrate-producing bacteria in the fecal 
microbiota. Interestingly, this effect was less clear in the late adult mice in relation 
to hepatic fibrosis development where we observed both positive (Clostridium 
sensu stricto, Clostridium XI) as well as a negative correlation (Clostridium XIVb, 
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Clostridiales, Clostridium XIVa) of the butyrate-producing bacteria of the Clostridia 
genus. To our knowledge, these findings are novel however the data should be 
interpreted with caution because microbiome analysis and pathology have been 
performed at the same time point and microbiome changes may merely reflect 
metabolic adaptation but might not be causal to development of the end points. It is 
intriguing that the microbiota changes upon butyrate treatment differ in mid-adult 
and late adult mice and that the two age groups also develop different pathologic 
endpoints.
Conclusion
We hypothesize that midlife obesity increases the risk of cognitive impairment via 
mainly inflammatory responses and vascular damage. These findings emphasize the 
association between midlife obesity and cognitive impairment in humans (3). We 
report novel insights in the impact of diet-induced obesity and butyrate in a genetic 
mouse model on brain function and structure during mid- and late adulthood. In 
mid-adult humans, butyrate supplementation may serve as potential preventative 
for obesity and obesity-related diseases, and in the long-run as preventative for 
dementia. 
Supplemental data:
https://www.nature.com/articles/ijo201752#supplementary-information
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Abstract
Adiposity and changes in adiposity are associated with cerebrovascular diseases, 
such as cerebral small vessel disease (CSVD) and its sequelae, vascular cognitive 
impairments (VCI) and dementias. Body mass index (BMI), waist circumference 
(WC), and blood leptin and total adiponectin levels were associated with CSVD 
and brain volumetry in 503 adults age ≥50 years enrolled in the Radboud University 
Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort (RUN DMC).
RUN DMC participants were followed for 9 years, from 2006 to 2015. BMI, WC, 
brain imaging and dementia diagnoses were evaluated at baseline and follow-up. 
Adipokines were measured at baseline. Brain imaging outcomes included CSVD 
components, white matter hyperintensities, lacunes and microbleeds; and gray and 
white matter, hippocampal, total brain, and intracranial volumes. 
Cross-sectionally among men at baseline, higher BMI, WC and leptin were 
associated with lower gray matter and total brain volumes, and higher BMI and 
WC were associated with lower hippocampal volume. At follow-up 9 years later, 
cross-sectional analyses showed associations between higher BMI and lower gray 
matter volume in men, and that an obese WC (>102cm) was protective for presence 
of >1 lacune or >1 microbleed in men. In women, increasing BMI and overweight 
or obesity (BMI >25 kg/m2 or WC >88 cm) were associated with >1 lacune. 
Anthropometric and metabolic adiposity indicators were differentially associated 
with CSVD and brain volumes by sex. Adiposity is associated with a vascular-neu-
rodegenerative spectrum that may influence and be influenced by brain pathologies 
associated with VCI and dementia. 
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Introduction
Approximately 50% of the global adult population is overweight or obese according 
to 2016 estimates, creating an obesity pandemic (1). Obesity during middle-age 
is associated with higher risk of several adult life cardiovascular risk factors and 
events including hypertension, hyperlipidemias, type 2 diabetes mellitus (T2DM), 
atherosclerosis, and myocardial infarction. These cardiovascular risk factors are 
subsequently associated with cerebrovascular events such as stroke and late-onset, 
sporadic dementias (315), in particular vascular cognitive impairments (VCI) and 
vascular forms of dementia (316). 
The biological mechanisms linking obesity to VCI and dementias and underlying 
cerebrovascular and neuro-pathologies are not well understood. However, one 
potential mechanism is that obesity represents higher amounts of adipose tissue, 
which contribute to alterations in the peripheral and cerebral circulation, which 
may be more pronounced with aging (317). In the brain, this translates to decreased 
cerebral blood flow and cerebral small vessel disease (CSVD), which is considered 
the major vascular contributor to dementia (318, 319). While CSVD cannot be 
diagnosed in vivo, it is operationalized by the presence of brain MRI markers 
including white matter hyperintensities (WMH), lacunes and microbleeds. 
Adipose tissue is the largest endocrine organ in the human body (77). 
Anthropometric measurements such as body mass index (BMI) and waist 
circumference (WC) are commonly used to estimate total and central adiposity, 
respectively. BMI grossly reflects total adult adiposity (5), whereas WC reflects the 
amount of highly bioactive visceral adipose tissue that surrounds internal organs 
(320). Secretory products of adipose tissue exhibit vascular and metabolic effects, 
and influence brain structure and function (77, 112, 321).
We examined the associations of anthropometric and metabolic measures of 
adiposity with MRI markers of CSVD (WMH, lacunes and microbleeds) and brain 
volumetry (gray and white matter, hippocampus and total brain). Given known sex 
differences in total and central adiposity, we stratified all analyses by sex. Identifying 
and understanding potential associations between potentially modifiable adiposity 
and CSVD, both of which increase risk for cognitive impairments and dementias, 
is important as this could facilitate interventions to reduce adverse effects of excess 
adiposity on public and personal health. 
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Methods
Study population
The RUN  DMC study prospectively investigates vascular and other factors associated 
with CSVD and CSVD progression among a baseline sample of 503 adults, aged 
50 to 85 years, with CSVD. Participants were recruited from consecutive patients 
referred to the department of Neurology of the Radboud university medical centre 
between October 2002 and November 2006, because they presented with symptoms 
of CSVD. These symptoms were acute, such as transient ischemic attack (TIA) or 
lacunar syndromes, but also subacute manifestations such as cognitive and motor 
(gait) disturbances (322). Patients were included based on age and the presence of 
CSVD on neuroimaging (WMH and/or lacunar infarcts) (322). Patients who were 
eligible because of a lacunar syndrome were included >6 months after the event to 
avoid acute effects on outcomes. 
Exclusion criteria were: (a) dementia; (b) parkinsonism; (c) intracranial 
hemorrhage; (d) life expectancy <6 months; (e) intracranial space-occupying 
lesion; (f) psychiatric or other disease interfering with cognitive testing or ability 
to be followed up; (g) recent or current use of acetylcholinesterase inhibitors, 
neuroleptic agents, L-dopa or dopamine agonists or antagonists; (h) non-CSVD 
WMH (e.g. multiple sclerosis); (i) prominent visual or hearing impairment; (j) 
language barrier; or (k) MRI contraindications, e.g., claustrophobia. 
Follow-up of participants after 9 years occurred among those who were alive and 
agreed to participate. Baseline participants were invited to follow-up via mail, with 
a follow-up telephone call to schedule their visit at our research center. During their 
follow-up visit, a subset of baseline assessments were re-administered, including a 
dementia assessment. All tests at baseline and follow-up were performed by two 
trained Neurology residents physicians.
All participants provided written informed consent. The study was approved by the 
Medical Review Ethics Committee region Arnhem-Nijmegen. 
Structured interview
A structured interview interview was done, which included on demographics, 
lifestyle, vascular risk factors, and current medication use. Demographics and 
lifestyle included education (classified using 7 categories, ranging from primary 
school to an academic degree), marital status, living conditions, and lifestyle 
habits (alcohol consumption, smoking). Vascular risk factors and cardiovascular 
disease included history of hypertension, T2DM, atrial fibrillation, TIA, stroke, 
myocardial infarction, coronary artery bypass graft, per-cutaneous transluminal 
coronary angiography, aortic prothesis, vascular prothesis, carotid endartectomy, 
and migraine. Family history of myocardial infarction, cerebrovascular disease and 
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diabetes mellitus was recorded. Current medication use was classified according to 
the anatomical therapeutic chemical (ATC) classification system (323). 
Physical examination
Anthropometric measurements included body mass index (BMI), calculated as 
clinically measured body weight divided by body height squared (kg/m2). Maximal 
waist circumference (WC) in centimeters (cm) was measured without a shirt, in 
a standing position, between the lowest rib and the iliac crest at the end of usual 
expiration.
Blood pressure measurements included systolic and diastolic pressures obtained in 
the sitting position. The average of three repeated measurements was used. 
Blood measures at baseline were collected after a 12-hour, overnight fast, and serum 
aliquots were stored at −80°C. A lipid panel comprised of total cholesterol, HDL, 
LDL and triglyceride, was measured. Total serum leptin and adiponectin levels were 
determined using human leptin and adiponectin enzyme-linked immunosorbent 
assays (ELISA) (Laboratory Medicine, Radboud University Medical Center, 
Nijmegen, The Netherlands). 
Magnetic Resonance Imaging protocol 
MRI images were acquired on a 1.5T MRI scanner (2006: Siemens (Munich, 
Germany), Magnetom Sonata, and 2015: Siemens, Magnetom Avanto) using 
the same head coil at both time points. The scanning protocol included 3D T1 
magnetization-prepared rapid gradient echo (MPRAGE) imaging (voxel size 
1.0x1.0x1.0 mm); and fluid-attenuated inversion recovery (FLAIR) pulse sequences 
(2006: voxel size 0.5x0.5x5.0 mm, interslice gap 1.0 mm, and 2015: voxel size 
0.5x0.5x2.5 mm; interslice gap 0.5 mm). To minimize effects of changes in FLAIR 
sequence, we re-sliced follow-up FLAIR images to match slice thickness of baseline 
images using linear interpolation (324).
Brain volumetry outcomes
MRI outcomes analyses have been described in detail (324). In brief, gray matter, 
white matter, hippocampal and cerebrospinal fluid (CSF) volumes were calculated 
using SPM12 (fil.ion.ucl.ac.uk/spm/) unified segmentation routines on the T1 
MPRAGE images (325). All images were visually checked for co-registration 
and segmentation artefacts. Gray matter volumes (GMV), white matter volumes 
(WMV), and CSF volumes were computed by summing all voxels belonging to 
that tissue class,  multiplied by voxel volume in milliliters. Intracranial volume 
(ICV) was determined by summing GMV, WMV, and CSF volume; and total brain 
volume (TBV) by summing GMV and WMV. To account for interscan effects, we 
corrected for differences in ICV between baseline and follow-up.  All volumes were 
normalized to baseline ICV to account for head size.
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CSVD outcomes
CSVD was rated using STRIVE criteria for vascular changes on neuroimaging 
(326). WMH volumes were calculated using a semiautomatic WMH segmentation 
method (327). Segmentations were visually checked for segmentation errors by 
one trained rater, blinded to clinical data. The Fazekas scale was used to categorize 
baseline WMH severity (328).
Number and location of lacunes and microbleeds were rated manually on FLAIR/
T1-weighted MRI scans according to the STRIVE criteria by 2 trained raters blinded 
to clinical data. Lacunes were defined as hypo-intense areas >2 mm and ≤15 mm on 
FLAIR and T1, ruling out enlarged perivascular spaces (≤2 mm, except around the 
anterior commissure, where perivascular spaces can be large) and infraputaminal 
pseudolacunes (329). Microbleeds were defined as small (<10 mm diameter), 
homogeneous, round foci of low signal intensity on T2* weighted images (330). 
Microbleed number per hemisphere was counted. Lesions were not considered 
microbleeds if they were symmetric hypointensities in the globus pallidus, likely 
calcifications or iron deposits (330). Inter-rater and intra-rater reliabilities were 
excellent (324). Incident lacunes and microbleeds during the follow-up period 
were identified (324). 
Dementia assessment
Dementia screening was performed at 9-year follow-up and has been described 
in detail (325). The mini–mental state examination (MMSE)(331) was the initial 
screening instrument of global cognition. A follow-up MMSE score <26 or a 
decline of >3 points from baseline was considered screening positive. Those 
who screened positive based on these criteria were subsequently examined for 
the presence of dementia at the Radboud Alzheimer Center Nijmegen, The 
Netherlands. If a participant refused additional examinations at the Alzheimer 
Center, a consensus panel consisting of a neurologist, clinical neuropsychologist, 
and a geriatrician made the dementia diagnosis. This panel reviewed all available 
neuropsychological (322) and brain imaging information, which included a) 
difference in neuropsychological performance between baseline and follow-up; b) 
outcome of the Mini International Neuropsychiatric Interview MINI (332); c) the 
follow-up MRI scan and/or baseline MRI-scan to determine dementia subtype; 
and d) medical record review. In addition, participants’ general practitioners and 
medical specialists were contacted regarding cognitive status. Cognitive tests were 
interpreted with consideration for age, level of education, and interference with 
daily living conﬁrmed by family or caregiver (333). The dementia diagnosis was 
based on the diagnostic and statistical manual of mental disorders (DSM) IV 
criteria (334). Dementia onset was established as the date when clinical symptoms 
were consistent with the diagnosis (335). 
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Statistical analyses
Baseline and follow-up cross-sectional analyses included descriptive analyses 
of all primary adiposity exposures and brain outcomes for the entire sample 
and by sex. Means and standard deviations (SD) were computed for continuous 
variables. Due to skewed distributions, leptin, adiponectin and WMH were natural 
log transformed. As leptin resistance is often observed in obesity, we estimated 
leptin resistance by calculating the leptin to BMI (leptin:BMI) ratio (336). Pearson 
correlation analyses were conducted among adiposity measures. T-tests were 
used for means comparisons. Chi-square analyses were conducted for categorical 
variables.
Multivariable linear and logistic regression models were used to examine 
cross-sectional associations between adiposity measures and CSVD and volumetric 
brain outcomes at both time points, 2006 and 2015. Regression models were run 
separately for each adiposity measure as an independent predictor. Adiposity 
measures included BMI and WC in 2006 and 2015; and leptin and total adiponectin 
in 2006 only. Brain imaging outcomes included CSVD components and brain 
volumes. Logistic regression analyses were used to predict the presence versus 
absence of CSVD components. Odds ratios (OR) and 95% Confidence Intervals 
(CI) were calculated. WMH, GMV, WMV, TBV and hippocampal volume (HV) 
were considered as continuous outcome variables in linear regression analyses. 
Beta-coefficients (b) and 95% CI were calculated. 
Given that CSVD and more severe change in body weight and BMI increases 
risk for dementia (337), we also examined change in anthropometric measures 
(BMI and WC) from 2006-2015 in association with MRI markers of CSVD and 
brain volumes measured in 2015. In analyses of anthropometric change, since 
no participant presents with the same body weight or BMI at two visits and ‘any 
change’ may not be informative, we categorized the sample by an a priori defined 
‘substantial’ degree of change, either >5% and >10% increase or decrease from 
baseline body weight and BMI. 
Selection of covariates originated from a pool of variables that were potentially 
biologically relevant and/or reported in the literature as CSVD risk and protective 
factors. Our pool consisted of age; sex; educational attainment (< primary education 
versus > primary education); cigarette smoking in pack-years (calculated as number 
of packs of cigarettes smoked per day multiplied by number of years smoked); 
alcohol intake (units per day); clinically relevant depressive symptom burden (≥16 
on the center of epidemiologic studies on depression scale (CES-D) or current 
depression medication use); MMSE score; use of glucose lowering medications; 
T2DM (self-reported or T2DM medication use); hypertension (blood pressure 
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≥140/90 mmHg or antihypertensive medication use); blood lipid levels; and 
hypercholesterolemia (cholesterol > 6.2mM or lipid-lowering drug use). From this 
pool, we systematically determined which ones to include in multivariable-adjusted 
regression models by evaluating each variable in age-adjusted regression models 
in association with brain MRI outcomes. If the variable was associated with an 
outcome at P<0.05, the variable was included as a covariate in the final regression 
model. As a result, age, sex, education (≤ primary school versus > primary school), 
cigarette smoking (ever/never), and T2DM (yes/no) were included. In analyses 
involving 2015 brain outcomes, presence of dementia and baseline WMH severity 
based on the Fazekas scale, were also included as covariates. Results for linear and 
logistic multivariable analyses were considered significant using two-tailed tests, 
P<0.05. SPSS, version 22.0 (IBM Corporation, Armonk, New York, USA), was used 
to conduct data analyses.
Results
Baseline characteristics of the RUN DMC baseline study population (N=503) 
are reported in Table 1. Mean age of participants at baseline was 65.6 ± 8.8 years, 
and at follow-up, 71.3 ± 7.9 years. Differences in baseline characteristics between 
participants and those who died during follow-up are also presented in Table 1. 
Compared to surviving participants, those who died during follow-up were older; 
had a lower MMSE score; had higher average WC; had higher prevalence of central 
obesity using sex-specific cut points; were more likely to use lipid- glucose- and 
blood pressure-lowering medications; and were more likely to have T2DM. Those 
who died also evidenced lower baseline TBV, GMV, WMV and HV; a higher 
median volume of WMH; and were more likely to have a Fazekas score of moderate 
or severe (versus none or mild) or possess > 1 lacune at baseline.  Thus, ‘healthier’ 
surviving participants were observed in 2015.
Adiposity indicators, CSVD markers, and brain volumes
Increasing BMI and WC, as well as total and central obesity were associated with 
lower GMV and TBV in all male participants cross-sectionally at average baseline 
age, 66 years (Table 2). Higher serum leptin levels were associated with lower GMV 
and TBV in the total sample of men and women. Increasing BMI and WC were also 
associated with lower HV in men (Table 2). Interestingly, a higher estimate of leptin 
resistance (leptin:BMI), was also associated with lower GMV and TBV, particularly 
in men. At follow-up 9 years later, average age 71 years, cross-sectional analyses 
showed increasing BMI associated with lower GMV; and higher WC with lower 
HV, particularly in men (Table 3). 
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Figure 1. RUN DMC study design 
In relation to CSVD outcomes, cross-sectionally at average age 66 years, leptin was 
protective in men. In particular, the highest quartile of leptin, compared to the 
lowest quartile, was associated with lower WMH volumes and lower odds of >1 
lacune. Cross-sectional analyses at 9-year follow-up, showed that an obese WC 
lowered the odds of microbleeds and lacunes in men (Table 4). However, in women, 
increasing BMI, being overweight or obese based on BMI, or having an obese WC 
were associated with the presence of >1 lacune (Table 4). 
Longitudinal analyses of baseline adiposity measures in association with CSVD and 
brain volumetry outcomes at follow-up 9 years later showed no associations (data 
not shown). Similarly, evaluation of 5% and 10% change in BMI and body weight 
over 9 years, showed no association with follow-up CSVD or brain volumetry 
outcomes (data not shown). 
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Table 1. Baseline and follow-up characteristics of participants, and baseline characteristics of 
those died during follow-up in the RUN DMC . aVascular risk factors assessed at baseline only. 
bSignificant at P<0.05 men versus women. cSignificant P<0.05 participants who died during 
follow up versus baseline. WMH: White Matter Hyperintensities. CSVD: cerebral small vessel 
disease. IQR: interquartile range. 
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Table 2. Linear regression models estimating baseline cross-sectional associations between 
adiposity exposures and brain volumes in RUN DMC. Linear regression models for gray 
matter, white matter and hippocampal volumes were adjusted for age, education, sex, smoking, 
and type 2 diabetes mellitus (T2DM). N: number of participants. Seven participants were 
excluded in the hippocampal analyses due to imaging artifacts (motion). β: beta, standardized 
regression coefficient. Continuous measures of total brain volume, gray matter volume, white 
matter volume and hippocampal volume (mL). Continuous levels of leptin and adiponectin 
are categorized in quartiles, and the lowest quartile (Q1) was compared to the highest quartile 
(Q4). aReferent category. bNo significant associations were observed for adiponectin quartiles 
(data not shown). 
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Table 3. Linear regression models estimating cross-sectional associations between 
anthropometric measures and brain volumes at 9-year follow-up in RUN DMC. Linear 
regression models for gray matter volume, white matte volume and hippocampal were 
adjusted for: age, education, sex, smoking, type 2 diabetes mellitus (T2DM), WMH severity, 
and dementia incidence. N: number of participants. Five participants were excluded in the 
hippocampal analyses due to imaging artifacts (motion). β: beta, standardized regression 
coefficient. Continuous measures of total brain volume, gray matter volume, white matter 
volume and hippocampal volume (mL). aReferent category.
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Table 4. Linear and logistic regression models estimating cross-sectional associations 
between adiposity exposures and cerebral Small Vessel Disease outcomes at 9-year 
follow-up in RUN DMC. Linear regression models for WMH were adjusted for: age, education, 
sex, smoking, type 2 diabetes mellitus (T2DM), CSVD severity, and dementia incidence. 
Logistic regression models for incident microbleeds were adjusted for: age, education, sex, 
WMH severity, and dementia incidence; and incident lacunes for: age, education, sex, smoking, 
hypertension, T2DM, CSVD severity, and dementia incidence. N: number of participants. 
Nine participants were excluded from microbleeds analyses due to imaging artifacts (motion). 
WMH: White Matter Hyperintensities. aReferent category.. bContinuous measures of WMH 
(mL), cpresence of any microbleeds or lacunes. CSVD: cerebral Small Vessel Disease. β: beta, 
standardized regression coefficient. OR: Odds Ratio. (95% CI): 95% Confidence Interval. 
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Discussion
To our knowledge, these data comprise a first report suggesting sex differences 
underlying associations of anthropometric and metabolic adiposity measures 
with cerebrovascular and neurodegenerative events in a clinical cohort of CSVD 
patients. Overweight and obesity, as well as higher leptin levels, in men with 
CSVD are associated with neurodegeneration, particularly in their 60s. However, 
among men with CSVD surviving into their 70s, higher adiposity is associated 
with fewer cerebrovascular markers. In contrast, women with CSVD and higher 
levels of adiposity in their 70s are more likely to experience lacunes and evidence 
no associations with neurodegeneration. These data also illustrate the nuances of 
following a healthier group of surviving participants with a clinically diagnosed 
cerebrovascular phenotype. Most observed associations occurred among men 
at two cross-sectional time points, at average age 66 years, and 9 years later at 
average age 71 years, with adverse associations with adiposity diminishing with 
survivorship. 
Associations of higher BMI and WC with underlying cerebrovascular pathologies 
such as white matter hyperintensities (WMH) (338), cerebral microbleeds (339) 
and lacunes (340) are sparsely reported in the literature. Most data suggest higher 
levels of vascular risk factors, including higher BMI and central obesity or visceral 
adipose, to be associated with higher cerebrovascular risk (318, 341). In addition, 
a J-shaped BMI curve, i.e. both low and high BMI, is associated with higher risk 
of intracerebral haemorrhage (342). Higher WC has been associated with CSVD 
components, notably characterized by microbleeds, lacunes, and WMH in Korean 
samples (318, 339).
In addition to considering cerebrovascular components of CSVD, we also evaluated 
neurodegeneration. Cross-sectional associations between higher anthropometric 
measurements and lower TBV, GMV and HV is comparable to others reporting 
that higher levels of anthropometric measures are associated with a lower TBV, 
GMV and HV (57, 343, 344). Higher BMI has been associated with lower brain 
volumes, particularly GMV, in adults (345, 346), including those with metabolic 
syndrome (347). Higher BMI and lower GMV have also been associated with lower 
cognitive function (80); as has central obesity (89). Visceral adipose tissue (highly 
correlated with WC) measured via abdominal MRI, has been associated with lower 
HV in cognitively healthy elderly age 55-90 years (348). Despite the majority of 
studies reporting associations between higher adiposity and lower brain volumes, 
there are conflicting reports. For example, higher BMI was associated with higher 
HV in older adults with or at risk for cardiovascular disease (349).  
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Our findings suggest that first, higher levels of adiposity, classified as anthropometric 
overweight and obesity, may be related to earlier neurodegenerative outcomes, 
such as lower TBV and GMV, and later protection for lacunes and microbleeds 
in men. In contrast, among women, higher levels of adiposity are related to later 
occurrence of at least one marker of vascular damage, lacunes. This suggests a 
cerebrovascular-neurodegenerative spectrum and distinct temporality of brain 
outcomes associated with adipose tissue exposures that differ between men and 
women with CSVD. Second, these findings emphasize that adipose tissue may play 
endocrine, neuronal and vascular roles in brain health (77, 104, 350). These roles 
may be both cause and consequence of cerebrovascular and neurodegenerative 
pathologies associated with CSVD and/or its clinical symptoms. Third, these data 
underscore the profound influence of selective survival in longitudinal analyses of 
brain outcomes, and imply a role of brain reserve in survival, since those who died 
during the follow-up period had lower baseline brain volumes.
From the standpoint of metabolic adipose tissue, higher blood leptin levels and 
calculated leptin resistance are associated with lower TBV and GMV in older 
adults, particularly men with CSVD. This is somewhat novel, especially for older 
adults. Higher blood leptin levels have been associated with lower GMV in young 
adults (mean age 32.0 ± 1.0 years) (351). Among adolescents (mean age 15.3 ± 
1.1 years) who gained body fat, there was observed greater GMV reduction in the 
putamen (352). Another study found higher leptin associated specifically with 
lower insula GMV among adults age 25-40 years who had a family history of 
obesity (353). Higher leptin levels are found in ischemic stroke patients (354). In 
contrast, among Japanese elderly, higher  blood leptin levels were associated with 
higher region-specific GMV, including in the hippocampus (355). Higher leptin 
levels have also been shown to protect against age-related cognitive decline(355) 
and dementia (111) in older adults. Given that leptin signaling is dysregulated 
in degenerating hippocampal neurons, potentially indicating neuronal leptin 
resistance in Alzheimer’s disease patients (356), inconsistent cross-sectional 
leptin associations with brain outcomes, cognition and dementias in older men 
may be obscured. Leptin may play a pivotal role in an aging fat-brain axis, as well 
as be a critical marker of aging-related changes in satiety, glucose homeostasis, 
inflammatory processes, vascular function, and memory formation (112, 117, 321, 
357-360). 
Sex differences in total and central obesity is a known phenomenon (361, 362). 
Differential storage of white adipose tissue is influenced by sex hormones, as well 
as fat depot-specific release of hormones and cytokines (363). Larger WC, a marker 
of visceral adipose tissue and denoting a more androgenic hormonal environment, 
is more common among adult men and postmenopausal women (364, 365),  and 
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associated with higher cardiovascular disease risk (366). Sex-specific associations 
between anthropometric measures and brain volumes are inconsistent. As 
aforementioned, higher BMI is associated with lower GMV in Japanese men (367); 
and with temporal lobe atrophy in women aged >70 years (368). Given that the 
average age of menopause is 52 years in northern European populations (369), 
our sample most likely includes women who were going through the menopausal 
transition. Menopause influences the sex hormone milieu (370), as well as body 
composition (365),  including adipose tissue and consequently, blood adipokine 
levels.
Differential associations between adiposity measures and brain outcomes may also 
be dependent on age of measurement and temporality. A changing role of adipose 
tissue throughout aging and in later life, by age decade, may be a real phenomenon. 
Our sample was examined on average, during their 7th and 8th decades of life. 
During this aging period, an inflection point in vascular risk factor trajectories 
has been observed. These trajectories are described for BMI, blood pressure and 
blood lipids in association with late-onset sporadic dementias (371-373). While we 
cannot evaluate life course trajectories in RUN DMC given a 9-year follow-up of 
adults age 50 years and older, their potential contribution to a changing risk profile, 
particularly among women, cannot be ignored. Midlife obesity has been associated 
with reduced GMV and greater dementia risk, whereas later life overweight and 
obesity has been associated with lower dementia risk (3, 343, 351, 368, 374). Given 
cross-sectional findings in RUN DMC, we cannot elucidate causality, nor gain 
insights regarding temporality of these associations.
Lack of associations between higher levels of adiposity measures and CSVD 
components, may be due to an attenuation of the role of vascular risk factors 
among those presenting with cerebrovascular disease, similar to observations 
in dementia epidemiology among those with prodromal dementias such as VCI 
(371, 375, 376). Given that aging- and dementia-related neurodegenerative events 
affect homeostatic regulation of energy balance, blood pressure and other aspects 
of metabolism, temporal paradoxical associations are often observed between 
vascular risk factors, such as obesity, and symptomatic, clinical  outcomes (3, 77, 
337, 363).
CSVD is a diagnosis that is evolving over time due to emerging phenotypic 
characterization and accumulating mechanistic evidence in association with 
clinical outcomes. CSVD is a group of pathological processes with a heterogeneous 
etiology and pathogenesis that involve the small arteries, arterioles, venules, and 
capillaries of the brain. In 2006, the baseline year of the RUN DMC, CSVD was 
diagnosed on the basis of the presence of any WMH and the presence of any lacunes 
(377), with accompanying acute symptoms (transient ischemic attacks or lacunar 
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syndromes), or subacute manifestations (cognitive, motor (gait) and/or mood 
disturbances) (378). Later recognized markers of CSVD, such as microbleeds, were 
also rated in RUN DMC. Therefore, our approach of evaluating adiposity measures 
in association with individual components of CSVD is appropriate, in addition to 
being more informative for intervention development. 
Longitudinal analyses of risk factors for CSVD and its components are challenged 
since WMH, lacunes and microbleeds change over time in ways that are difficult 
to characterize. In RUN DMC, it was reported (324) that CSVD progression is 
nonlinear, accelerating over time, and is a dynamic process, with progression 
interrupted by reduction in some adults who, on average, show progression. RUN 
DMC has also reported the disappearance of lacunes and microbleeds over this 
9-year follow-up period. In RUN DMC, these unexpected changes tended to occur 
among those presenting with a worse CSVD phenotype at baseline. Since RUN 
DMC participants who died during the 9-year follow-up had worse baseline CSVD 
and volumetric phenotypes compared to those who survived and participated in 
2015, and there is worsening of CSVD on average among surviving participants, 
our longitudinal results are not as likely influenced by these unexpected changes. 
Major strengths of our analyses are the following. First, this report is based on 
9-year follow-up of men and women presenting with a distinct cerebrovascular 
phenotype, CSVD, with quantified neurodegenerative outcomes, notably brain 
volumetry, and thorough clinical and risk factor evaluation. Second, brain imaging 
data were analyzed by raters who were blind to clinical information, with good 
inter- and intra-rater agreement. Third, statistical analyses were adjusted for 
multiple potential confounders. Fourth, while our primary exposure was adiposity, 
we measured this phenotype in several ways. Using anthropometric (total and 
central obesity) and metabolic (leptin and adiponectin) markers of adipose tissue, 
differential associations were observed. This may point to different mechanistic 
pathways linking adipose tissue biology to neurodegeneration and cerebrovascular 
events. Fifth, multiple brain imaging outcomes were investigated. This is important 
for more precise determination of etiologic mechanisms associated with adiposity.
Despite the aforementioned strengths, several limitations should be addressed. 
First, serum leptin, adiponectin and lipid levels, were not measured at the follow-up 
examination; blood was only collected at baseline. Second, sociodemographic and 
health status information was not updated at follow-up in the RUN DMC. Third, 
nutritional intake and physical activity, known influencers of overweight and 
obesity, were not measured. Fourth, RUN DMC participants were all diagnosed 
with CSVD, which makes it difficult to generalize these results to an otherwise 
‘healthy’ older population. It is also known that CSVD brain pathologies exist 
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without symptomatic burden (‘silent’ or preclinical CSVD) and are relatively 
common among elderly. Fifth, the RUN DMC sample is comprised of Dutch adults 
of northern European ancestry. These results require replication in heterogeneous 
samples due to global variations in anthropometric and brain characteristics 
(315, 379). Sixth, due to the small number of adults developing dementia, it could 
not be evaluated as a clinical endpoint. Finally, no information was available on 
menopausal status of women. 
In conclusion, our analyses demonstrate sex differences in a potential manifestation 
of the fat-brain axis, and different cross-sectional and longitudinal adiposity-brain 
associations with aging over a 9-year period in men and women with CSVD. Future 
research is necessary to elucidate biological mechanisms and fat-brain associations 
over the life course. Elucidation of both independent and interdependent 
neuropathological versus vascular mechanisms underpinning the evolving aging 
brain is imperative.
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Abstract 
Adiposity measured in mid- or late-life, and estimated using anthropometric 
measures such as body mass index (BMI) and waist-to-hip ratio (WHR), or 
metabolic markers such as blood leptin and adiponectin levels, is associated with 
late-onset dementia risk. However, during later life this association may reverse and 
aging- and dementia-related processes may differentially affect adiposity measures. 
We explored associations of concurrent BMI, WHR, and blood leptin and high 
molecular weight adiponectin levels with dementia occurrence.
924 Swedish community-dwelling elderly without dementia, aged 70 years and 
older, systematically-sampled by birth day and birth year population-based in 
the Gothenburg city region of Sweden. The Gothenburg Birth Cohort Studies are 
designed for evaluating risk and protective factors for dementia. All dementias 
diagnosed after age 70 for 10 years were identified. Multivariable logistic regression 
models were used to predict dementia occurrence between 2000-2005, 2005-2010, 
and 2000-2010 after excluding prevalent baseline (year 2000) dementias. Baseline 
levels of BMI, WHR, leptin and adiponectin were used.
Within 5 years of baseline, low BMI (<20 kg/m2) was associated with higher odds 
of dementia compared to those in the healthy BMI category (≥ 20-24.9 kg/ m2). 
Compared to the lowest quartile, leptin levels in the second quartile were associated 
with lower odds of dementia in women (P<0.05). 
In late-life, anthropometric and metabolic adiposity measures appear to be 
differentially associated with dementia risk. While BMI and leptin levels are highly 
positively correlated, our results show that their association with dementia at age ≥ 
70 years, is asynchronous. These data suggest that with aging, the complexity of the 
adiposity exposure may increase and suggests metabolic dysregulation. Additional 
studies are needed to better understand this complexity.
89
Adiposity indicators and dementia in elderly
5
Introduction
In later life, lower body mass index (BMI), being underweight by definition, and 
declining BMI (despite one’s BMI level at onset of decline), are associated with 
greater risk of late-onset dementias (3, 380). In mid- or adult life, higher BMI is 
prospectively associated with dementia risk (3). This difference in the mid-life 
versus late-life BMI-dementia risk association is often referred to as the ‘obesity 
paradox’ and evidence of reverse causality (315). 
Anthropometric characteristics are sculpted by amount and distribution of 
adipose tissue. Changes in this important tissue result from lifetime variations 
in energy balance, sociocultural background, and epigenetic phenomena, and 
develop secondarily to central pathophysiological changes in preclinical and 
clinical dementia (381). Therefore, adiposity indicators like BMI, waist-hip ratio 
(WHR), and circulating blood levels of adipokines, such as leptin and adiponectin, 
are potential risk markers for dementia (88, 382-384). Since adipose tissue is 
the primary source of both of these adipokines, leptin and adiponectin are good 
biomarkers of this tissue’s metabolic activity. 
There is limited and ambiguous published research regarding the link between 
adipokine levels and sporadic, late-onset dementias (360, 385). However, leptin 
is associated with insulin resistance and brain health (77, 88), and is the adipose 
tissue hormone (111) most studied in association with brain structure and 
function. Leptin has numerous effects on brain development (110), and potentially 
on brain health in cognition and aging. Peripheral leptin enters the central nervous 
system and interacts with specific areas of the brain such as the hypothalamus and 
hippocampus (386). In addition to crossing the blood brain barrier (BBB) (387), 
several studies indicate that leptin is also produced in the brain, for example in the 
hypothalamus, cortex and cerebellum (388, 389). Leptin has been prospectively 
associated with dementia over 8 years (111), but not over 24 years, from mid- to 
late-life (368). Leptin is positively correlated with total and central anthropometric 
adiposity measures (390, 391). 
Adiponectin is a visceral adipose tissue marker and exists as complex multimeric 
isoforms comprised of high molecular weight (HMW) hexamers and trimers (392). 
It is an effective insulin sensitizer, and circulating levels are inversely correlated with 
insulin resistance, metabolic syndrome, adiposity, type 2 diabetes mellitus, and 
cardiovascular diseases. Adiponectin modulates inflammatory responses, energy 
expenditure (CNS and periphery), food intake (CNS), and a number of metabolic 
processes, including glucose regulation and fatty acid catabolism in the periphery. 
Since BBB transport mechanisms for adiponectin are unclear, blood levels may not 
indicate potential interactions between adiponectin and the brain (393).
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We investigated the association between dementia occurrence and both 
anthropometric and adipokine indicators of adiposity - BMI, WHR, and blood 
leptin and adiponectin levels - in a 10-year prospective population-based study 
of Swedish adults, aged 70 years and older. Moreover, we examined whether these 
adiposity markers predict dementia occurrence over the short- and/or long-term. 
This study will further reveal the complex interplay between surrogate markers of 
adiposity and dementia onset.
Methods
Participants
Participants comprising the Gothenburg Birth Cohort Studies, originate from two 
epidemiological studies in Gothenburg, Sweden: 1) the Prospective Population 
Study of Women (PPSW) and 2) the Gerontological and Geriatric Population 
Studies (H70). Both have been described in detail previously (394-396). Eligible 
participants were sampled from the Swedish Population Register based on birth 
date. PPSW participants were born in 1908, 1914, 1918, 1922 and 1930. H70 
participants were born in 1930. Adults living in private households and residential 
care were included. There were 1725 eligible individuals in 2000-2001, and 1018 
agreed to participate (response rate 59.0%). Among these, 857 (84.2%) consented 
to genetic analyses. Due to the nature of PPSW and H70, women (n=700) were 
70-92 years and men (n=224) 70 years. Participants included 339 H70 females at 
age 70, 224 H70 males at age 70, and 361 PPSW females age 70 years and older 
(Fig. 1). Follow-up examinations were conducted in 2005-06 and 2009-10, and 
689 participated in 2005-06 (response rate among survivors, 82.2%), and 518 in 
2009-10 (response rate among survivors, 76.7%). 
Those who died, or declined participation during follow-up, were traced in records 
from hospitals and homes for the aged, inpatient and outpatient departments in 
psychiatric hospitals and clinics, municipal psychiatric outpatient departments 
in Gothenburg, the hospital-linkage system, and death certificates (397). All 
participants (or their closest relatives) gave informed consent, which was conducted 
in accordance to the provisions of the Helsinki Declaration. The study was approved 
by the Ethics Committee for Medical Research at the University of Gothenburg.
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Figure 1. Flowchart of participant characteristics and number at baseline and in follow-up 
examinations.
Dementia assessment
Dementia diagnoses were made according to the diagnostic and statistical manual 
of mental disorders 3rd edition revised (DSM-III-R) (334, 398) at examinations in 
2000-2001, 2005-2006 and 2009-2010. This dementia diagnosis was made according 
to components of the Alzheimer’s disease assessment scale-cognitive subscale 
(ADAS-Cog). A close informant interview was conducted using IQCode (399). 
Symptom domains relevant for making a dementia diagnosis include: memory 
(short-term, long-term), aphasia (language disturbance), apraxia (inability to 
carry out motor activities despite intact function), agnosia (failure to identify or 
recognize objects despite intact sensory function), executive function (planning, 
organizing, abstract thinking) and personality changes (used in DSM-IIIR criteria 
for dementia, not in DSM-IV or DSM-V). Participants must have evidenced 
significant impairment in social or occupational functioning representing 
significant decline from a previous level of functioning. There was also a global 
rating of symptom status made by the interviewer (psychiatrist or psychiatric 
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nurse) and information from close informants related to dementia symptoms. The 
comprehensive psychiatric rating scale (CPRS) (400), an extensive neuropsychiatric 
inventory, was used to rate psychiatric symptoms and signs at face-to-face 
examinations. The mini-mental examination (MMSE) was used as an additional 
evaluation of global cognitive impairment, but is not considered diagnostic by 
itself. In addition, the Swedish Hospital Discharge Registry provided diagnostic 
information for individuals discharged from hospitals since 1978. Medical records 
were collected from hospitals and outpatient departments in Sweden’s public 
health care system. Incident cases of dementia up to December 31, 2010 were also 
based on information from the Swedish Hospital Discharge Register (ICD-10: 
F00.1, F01.8, F01.9, F03.9, G30.9). Thus, dementia diagnoses were obtained for all 
study participants, since almost all people in Sweden receive health care from the 
community and have an equal chance of having a medical record. Dementia was 
diagnosed by neuropsychiatrists at consensus meetings based on all information 
sources available, e.g., neuropsychiatric examinations, medical records, and close 
informant interviews.
Anthropometric assessments
Anthropometric measurements were conducted in the morning when participants 
wore light clothing at each examination (401). Body weight was recorded to the 
nearest 0.1 kg, and body height was measured to the nearest 0.5 cm. BMI was 
calculated as kg/m2. Waist and hip circumferences were measured to the nearest 
0.5 cm. Measures of each were conducted until there was agreement within 0.5 cm. 
Blood measures
Blood samples were collected after a 12-hour fast, and plasma aliquots stored at 
−70°C. Regarding baseline adipokine measures, control standards and participant 
samples were tested in duplicate using high molecular weight (HMW) adiponectin 
and leptin ELISA assays (Linco Research, Inc, St. Louis, MO 63304) in the Clinical 
Chemistry Department at the University of Gothenburg. Blood lipids including 
cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and 
triglycerides, were measured at the certified Sahlgrenska Hospital Laboratory. 
DNA was extracted from blood samples according to standard procedures. APOE 
(gene map locus 19q13.2) genotyping was performed by mini-sequencing as 
previously described in detail (402). Genotypes were obtained for the two SNPs 
(rs7412 and rs429358), which are used to unambiguously define e2, e3, and e4 
alleles. 
Lifestyle assessments and medical history
Level of education (completing six years compulsory education or less vs at least 
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compulsory education); socioeconomic status (SES, working vs middle/upper class); 
alcohol consumption and cigarette smoking (ever vs never use); medication use; 
and medical history were queried at each examination. Diagnoses of myocardial 
infarction, stroke, cancer, and diabetes were self-reported as well as determined by 
clinical examinations (ECG and blood samples), case records, hospital discharge 
registry, national cancer registry, and national stroke registry. Systolic (SBP) and 
diastolic blood pressures (DBP) were measured while participants were sitting 
down and at rest for at least 5 minutes. Depressive symptoms were measured using 
the Montgomery–Åsberg depression rating scale (MADRS) (403). 
Statistical analyses
Means and standard deviations were calculated for all continuous variables, and 
frequencies and percentages for categorical variables. BMI, WHR, leptin and 
adiponectin were used in analyses as continuous, and as traditional quartiled 
categorical variables. We considered baseline adiposity exposures at 2000 and 
2005, and percent BMI change from 2000-2005 in association with dementia 
occurring between 2005 and 2010. Clinically relevant BMI change was categorized 
as +/- > 5%, and +/- >10%. We created combined anthropometric and adipokine 
categories as potentially better surrogates of adiposity-associated risk (404, 405). 
We cross-tabulated leptin quartiles by the four traditional BMI (underweight, 
<20.00 kg/m2; healthy, 20.00 - 24.99 kg/m2; overweight, 25.00 - 29.99 kg/m2; and 
obese ≥30.00 kg/m2) categories. In other words, those with a low leptin and low 
BMI were compared to those with a high leptin and high BMI, versus either alone. 
Similarly, leptin quartiles were cross-tabulated by WHR (central obesity: men 
>0.90 cm, women >0.85).
Multivariable logistic regression analyses were used to calculate odds ratios (OR) 
for developing dementia over different time periods. First, regression models 
estimated the odds of dementia over ten years (2000-2010) given adiposity exposures 
measured at baseline in 2000. Second, we estimated the association between 
baseline adiposity indicators measured in 2000 among those without dementia 
and subsequent dementia occurring during two five year periods, 2000-2005 and 
2005-2010. To reiterate, prevalent dementia cases at baseline were excluded from 
all models. In models predicting dementia by adipokines, we adjusted for BMI if 
the correlation between adipokine and BMI did not exceed r ≥ 0.70. 
Selection of covariates originated from a pool of potentially biologically relevant 
variables: age; sex; education; socioeconomic status (SES); smoking; alcohol intake; 
depressive symptoms; diabetes; cancer; heart attack; stroke/transient ischemic attack; 
hypertension; blood triglyceride, cholesterol, HDL, LDL, and glucose levels; DBP; 
SBP; and APOEε4 genotype. All potential covariates were included in age-adjusted 
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logistic regression models predicting dementia over the entire follow-up period. 
Age, sex, SES, smoking status (ever/never), diabetes (yes/no), alcohol intake (ever/
never), depressive symptoms (MADRS score > 12), and presence of at least one 
APOEε4 allele were significant at P≤0.05 and included in multivariable models. 
Two-tailed tests were used with a significance level of P≤0.05. SPSS, version 20.0 
(IBM Corporation, Armonk, New York, USA), was used to perform data analyses.
Results
Overall, 924 adults (224 men and 700 women) without dementia, participated 
in the baseline (year 2000) examination. PPSW and H70 were representative of 
the population base with regard to sex; marital status; income; community rent 
allowance for those who could not afford housing; rate of inpatient and outpatient 
care in psychiatric hospitals, clinics, and municipal outpatient departments; and 
rates of registration with the Temperance Board (national registry for alcohol 
abuse). Over ten years, 134 participants developed dementia. 
The average age of the participants at baseline (n=924) was 74.0 years, and when 
stratified by sex, the average age of men was 70.0 years and for women, 75.3 years 
(Table 1). Compared to men, women were more likely to be underweight and had 
higher plasma levels of leptin and adiponectin. Approximately 25% of the study 
population had at least one APOEε4 allele (27.7% in men and 24.4% in women). 
Multivariable logistic regression models were used to examine the relationship 
between continuous baseline adiposity indicators and subsequent dementias. No 
associations were found between BMI, WHR, leptin or adiponectin and dementia 
occurrence in the entire sample over the ten year follow up (Table 2; data not shown 
for adipokines). 
To better understand the temporality of association between adiposity markers and 
dementia, we divided the ten year follow-up period into two five year dementia 
occurrence intervals - 2000-2005 and 2005-2010 (Table 2), as has been done 
previously (406). When analyzed continuously, a higher baseline BMI lowered the 
odds of dementia within five years. However, using traditional BMI categories, 
participants with an ‘underweight’ BMI (< 20 kg/m2) had higher odds of developing 
dementia compared to participants with a ‘healthy’ BMI (reference category BMI 
20.00-24.9 kg/m2) (Table 2). This finding among underweight may have driven the 
protective association observed when BMI was modelled as a continuous variable. 
This association was driven by female participants (Table 2). 
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Table 1. Baseline characteristics of participants without dementia in the Gothenburg 
Birth Cohort Studies.*Clinically relevant depressive symptom burden, MADRS score > 12. 
†APOEε4 allele: apolipoprotein epsilon 4 allele.
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In women, we also found an association between leptin levels and odds of dementia 
within the first five years of follow up (2000-2005, Table 3). No associations were 
observed in men. Baseline leptin levels in the second quartile (18.66 - 30.52 ng/mL) 
were associated with lower odds of developing dementia compared to leptin levels 
in the first quartile (≤18.65 ng/mL, reference). No associations were found between 
serum levels of HMW adiponectin and dementia occurrence.
Considering only dementias occurring during 2005-2010, there were no 
associations with baseline BMI, WHR, leptin or adiponectin (Table 2). In addition, 
BMI change from 2000-2005 was not associated with dementias occurring from 
2005-2010 (data not shown). Combinations of anthropometric BMI or WHR risk 
categories by leptin quartiles did not shed any additional light on these associations 
(data not shown). 
Table 2. Odds of developing dementia from 2000-2010, 2000-2005, and 2005-2010 by 
baseline BMI and WHR among participants without dementia. The Gothenburg Birth 
Cohort Studies. Multivariable models included the following covariates: in 2000-2010, age, 
sex, socio-economic status (SES), ApoEε4 allele, and smoking; in 2000-2005, age, sex, depressive 
symptoms and SES; in 2005-2010, age, sex and smoking. †Reference category. Multivariable 
models were assessed for the complete cohort (total), and subsequent for both men and women 
in the cohort. Low WHR: men ≤ 0.90 cm, women ≤ 0.85; High WHR: men > 0.90 cm, women 
> 0.85. Number of incident dementias in 2000-2010, N=134 (men N=18 and women N=116); 
in 2000-2005, N=68 (men N=8 and women N=60); and in 2005-2010, N=66 (men N=10 and 
women N=56). * NE: not estimable due to small number. *P<0.05; ** P<0.001.
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Table 3. Odds of developing dementia from 2000-2010, 2000-2005, and 2005-2010 by 
baseline leptin and adiponectin among participants without dementia. The Gothenburg 
Birth Cohort Studies. Multivariable models include in 2000-2010, age, sex, social economic 
status (SES), ApoEε4 allele, and smoking; in 2000-2005, age, sex, depressive symptoms and 
SES; in 2005-2010, age, sex and smoking. †Reference category. Multivariable models were 
assessed for the complete cohort (total), and subsequent for men and women. In adiponectin 
analyses BMI was included as covariate. NE: not estimable due to small number. Number of 
incident dementias in: 2000-2010, N=134 (men N=18 and women N=116), 2000-2005 N=68 
(men N=8 and women N=60). 
Discussion
In an elderly Swedish sample of women and men, we observed that a low BMI (<20 
kg/m2) was associated with over a 5-fold higher odds of developing dementia within 
five years in women, aged 70 years and older. Given published literature on mid-life 
obesity and later onset dementia, this may be evidence of an obesity paradox and/
or reverse causality. However, without mid-life measures, we cannot be sure. In 
addition, the odds of developing dementia were 70% lower in women aged 70 years 
and older who had intermediate serum leptin levels based on analysis of leptin 
quartiles. Thus, despite a robust correlation of r =0.71 between BMI and leptin in 
this sample, there is a suggestion that these adiposity indicators were differentially 
associated with development of dementia within 5 years of measurement in elderly 
women. 
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Other studies in middle-aged and elderly women have suggested contradictory 
associations between anthropometric versus leptin levels and cognition or dementia 
(360, 407, 408). 
Our analyses support a first-ever published report from the original Gothenburg 
Birth Cohort Study (H70) among those born 1901/02 (406). Similar to the 2003 
report, there was no association between higher BMI and dementia observed during 
the first 10 years of follow-up. In contrast to the 2003 report, the current analysis 
includes primarily those born 1930. Thus, with further follow-up, we will be able to 
observe a 30 year cohort comparison of the BMI-dementia association. In addition, 
we also chose to focus on all dementias, due to controversies and changes in the 
field regarding diagnoses of dementia subtypes without the use of neuroimaging or 
cerebrospinal fluid biomarkers (409).
Our study has many advantages. First, the population sample is part of a 
long-standing series of rich longitudinal birth cohort studies in Sweden beginning 
in 1968 (PPSW) and 1971 (the first H70 cohort) (394, 395), with consistent 
measures over time among unique birth cohorts. Second, there is long follow-up of 
a large sample of rigorously studied elderly, age 70 years and older, and adjustment 
for multiple potential confounders. Third, we measured blood levels of adipokines 
reflecting the metabolic activity of adipose tissue. Finally, we used the study design 
to our advantage, to estimate temporal (shorter versus longer term) associations 
of adiposity indicators with dementia. Given the important role of temporality in 
understanding risk and protective factor-dementia associations, we see this as a 
definite strength of these studies. 
As with any study design, there are limitations. First, while data from the 
Gothenburg Birth Cohort Studies have been published using this merged sample 
examined with identical methods by the same research group at the same time (410, 
411), the study is unbalanced regarding sex and age. All men were aged 70 years 
at baseline, whereas women were aged 70 years and older. Thus, our observations 
regarding sex differences should be interpreted cautiously. Second, a small number 
of male participants reduced the power for analyzing associations in men given that 
dementia onset was monitored during a period of relatively low risk, notably the 8th 
decade of life (406). Third, leptin and adiponectin measures were only measured 
at baseline, thus repeated measures and change in these important hormones over 
time cannot be considered. Fourth, other nutritional influencers of BMI and WHR, 
including estimates of energy intake and expenditure, are unavailable. Fifth, our 
leptin findings are rather conservative. While leptin has strong mechanistic actions 
in the brain, the use of this marker in the periphery as a reflection of the fat-brain 
axis remains unclear, especially at a life stage when there are ageing-related body 
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composition changes. In addition, replication of our observations regarding leptin 
is essential. Finally, some may deem four and five year examination intervals to 
characterize date of dementia onset as unacceptable. However, given the insidious 
and often slowly progressive course of dementia onset and a population-based 
sample, we deem it highly acceptable for these types of analyses. Calculating odds 
ratios (OR), given this nuance, closely approximates the risk. We have shown this 
in a previous publication on adiposity measures and dementia (406).
While we found that the odds of developing dementia are higher in elderly women 
with low BMI within five years, this is not a new finding. The association between 
BMI and dementia appears to change over the life course. Some studies show that 
adults with a high midlife BMI or central obesity have a higher risk of late-life 
dementia (3). Others have reported that weight loss or BMI decline is associated 
with dementia risk in elderly (71, 73). Our data did not suggest associations of 
baseline BMI and dementias occurring between 2000-2010 nor dementias 
occurring between 2005 and 2010. Nor was BMI change from 2000-2005 related to 
dementias occurring between 2005-2010. This suggests temporal issues regarding 
the BMI-dementia association in this sample, however we cannot evaluate this 
historically since we do not have measures of BMI prior to 70 years. Thus, a lower 
BMI may be a preclinical marker for underlying dementia development within five 
years of a clinical diagnosis in women aged 70 years and older. These results should 
be interpreted with caution due to a small number of women in the lowest BMI 
category. The association of lower baseline BMI with dementia may result from a 
lengthier period of weight loss accompanying prodromal dementia prior to age 70 
years, supporting BMI as a possible preclinical marker of dementia. 
That low BMI may be a preclinical marker for dementia, is suggested by 
neuropathophysiological changes accompanying dementia. These changes can 
induce changes in body weight and adipose storage. For example, brain areas that 
control weight (i.e. mesial temporal cortex) are affected during the preclinical 
dementia phase; and adipose tissue loss may result from preclinical apathy, reduced 
olfactory function, difficulty with eating (e.g., aphasia), inadequate nutrition or 
prescribed medicines targeting dementia related symptoms e.g. depression or 
cognitive impairments (337). 
Furthermore, we found that the odds of developing dementia in elderly women 
were lower among those with intermediate blood leptin levels. Postmenopausal 
women may have a greater risk of developing dementia than men, perhaps due to 
changes in leptin and brain function due to a fall in endogenous estrogen levels 
following menopause (412). Estrogen and leptin have neuroprotective effects on 
cognition by regulating neurogenesis, hippocampal synaptic plasticity, and axonal 
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growth (77). However, the roles of adipokines are diverse, and often enigmatic. The 
adiposity-dementia association, remains to be elucidated, as this is by no means 
clear. 
As higher levels of adiposity, commonly measured as anthropometric overweight 
and obesity, are associated with higher risk for cardiovascular disease (CVD) 
(85, 87), and CVD is a risk factor for dementia (67), we explored CVD variables 
as potential covariates. None were significantly associated with dementia in 
age-adjusted models. This null observation associating dementia with CVD risk 
in late-life concurs with other published reports (65). In addition, adiponectin, 
known to be associated with CVD, was not associated with dementia. 
The underlying neurodegenerative and vascular pathologies observed in dementia, 
and subsequent impairment of key fat-brain and gut-brain feedback loops (413), 
may be at the root of conflicting observations; and seemingly intertwined adiposity 
factors may be differentially associated with dementia when measured within 
five years. Our findings are supported by studies reporting that higher levels of 
leptin are prospectively associated with lower odds of dementia or mild-cognitive 
impairment in elderly (360, 414, 415). Metabolic dysregulation may accompany 
or promote late-life alternations in leptin levels and dementias (416). Atrophy of 
the posterior hypothalamus affects appetite and feeding behavior via disintegration 
of network connections and effects on hormone synthesis (416, 417). In addition, 
higher levels of leptin are observed to be neuroprotective (418). 
Conclusion
Two highly correlated adiposity variables measured in late life do not associate 
similarly with late-onset dementia in women. Our analyses show a higher odds of 
dementia with a low BMI, and a lower odds of dementia with intermediate leptin 
levels when dementia occurs within 5 years of the adiposity measurement among 
women aged 70 years and older. Lower BMI and higher leptin may potentially 
characterize aspects of metabolic dysregulation associated with presence versus 
absence of prodromal dementia. However, both associations suggest a similar 
adiposity phenomenon, whether cast as lower BMI being risky or higher leptin 
levels being protective.
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Chapter 6
General discussion
In 2015, nearly 40% of the adult population in the United States was obese, and the 
obesity epidemic is still rising (419). Obesity is characterized by accumulation of 
white adipose tissue (WAT; adiposity), which eventually may have adverse effects 
on human health and cognition. Accumulation of WAT is potentially modifiable, 
therefore it is important to identify and better understand affected mechanisms 
in the adiposity-brain-axis. Eventually, knowledge on the adiposity-brain-axis 
may facilitate interventions to reduce the impact on public health. Therefore, with 
the research performed in this thesis we aimed to reveal mechanisms underlying 
the adiposity-brain-axis, in particular the involvement of cerebrovasculature, 
adipokines and aging, and the effects of fatty acids in these mechanisms in both 
mice and men. In this General discussion, it will be considered to what extend the 
results of the experiments described in the previous chapters may elucidate the 
adiposity-brain-axis.
Mouse models
Transgenic mice models are commonly used in preclinical obesity research, because 
in a relatively short period of time diet-induced-adiposity can be provoked, and/
or the susceptibility to develop co-morbidities like cardiovascular disorders. In 
our preclinical studies (Chapter 2 and 3), we examined the ApoE3*Leiden and 
low-density lipoprotein receptor knock-out Leiden (LDLr-/-) mouse models. Both 
mouse models are susceptible for accumulation of WAT, and the development 
of cardiovascular disorders like atherosclerosis and hypertension. We elucidated 
cerebral blood flow (CBF), structural brain changes and functional connectivity in 
these mouse models using high resolution (11.7 Tesla) magnetic resonance imaging 
(MRI)-scanner. Thereby, we were, to our knowledge, one of the first examining 
these parameters at this high resolution in context of rodent obesity. Nevertheless, 
there are some limitations concerning mouse models. For instance, anesthesia is a 
limitation within MRI research in rodent models. Anesthesia is stressful, induces 
hyperglycemia, and some types of anesthesia are stored within WAT (420). 
Secondly, metabolic phenotypes vary between mouse strains, and even vary 
between subpopulations of the same strain. For instance, C57BL/6J (The Jackson 
Laboratory) mice are predisposed to the obese and diabetic phenotypes, and show 
impaired insulin secretion compared to C57BL/6N (NIH) mice (421). Moreover, 
transgenic mouse models are characterized by pathological features. For instance, 
the LDLr-/- mouse model is susceptible to develop adiposity, hyperlipidemia, and 
atherosclerosis (Chapter 3). In detail, the loss of hepatic low-density lipoprotein 
receptor (LDLr) expression can increase circulating lipoproteins providing 
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increased triglyceride substrate for uptake by adipocytes (422). Alternatively, loss 
of the LDLr may have indirect effects on reducing lipolysis in adipocytes or altering 
thermogenesis, which would also increase lipid storage in WAT (422). The exact 
biological mechanisms involving lipid intake and accumulation in specific adipose 
depots is still under debate in the LDLr-/- mouse model, which might complicate 
the comparison of findings in this mouse model compared to other mouse models. 
Therefore, it is important to recognize the details of genetic background when 
interpreting experimental results, and the affected biological mechanisms involved 
in transgenic mouse models.
Thirdly, it remains challenging to compare mice to humans, particularly aging 
effects as for instance mice exert a maturation phase of 12 weeks which includes 
three weeks of weaning. Thus compared with humans, mice have an accelerated 
maturation rate during childhood because they develop rapidly during infancy (150 
times faster than humans), and generally, at 3–7 months are considered mature 
adults, equivalent to 20–30 years in human (421, 423). These limitations of mouse 
models must be taken into account when designing an experiment. Some possible 
directions to overcome these limitations could be elucidating the exact biological 
processes affected in transgenic mouse models. And last, the use of a standardized 
method such as proposed by the ARRIVE guidelines (286). Nevertheless, animal 
models still have the potential and are indispensable for examining biological 
mechanisms in anatomical, metabolic, and neurochemical detail. 
Cerebral circulation
The influence of adiposity on the vasculature may play a key role in the development 
of cognitive impairment, and dementia (424, 425). In detail, adiposity can induce 
atherosclerosis in large cerebral arteries, and more importantly it can impair the 
cerebral microcirculation (425). Alterations in cerebral circulation can induce a 
decreased cerebral blood flow (CBF; hypoperfusion) or cerebral small vessel disease 
(CSVD) (318, 319, 339). CSVD can be diagnosed by markers like white matter 
hyperintensities (WMH), lacunes and microbleeds using MRI imaging. Biological 
mechanisms involved are inflammation, loss of pericyte coverage on cerebral 
microvessels, blood brain barrier disruption, altered hippocampal angiogenic gene 
expression (282, 317). Alterations within the cerebral circulation can contribute 
to cognitive impairment as CBF is essential for normal neuronal function (319). 
Obese individuals often have an increased systolic blood pressure, and reduced 
CBF (18, 426). In chapter 3 we reinforce these finding in obese mice. Nevertheless, 
in a model for mild obesity we found reverse effects in CBF (Chapter 2). Plausibly, 
the blood vessel walls in the relatively mild obese ApoE3*Leiden mouse model were 
not severely affected or atherosclerotic, and may still be able to compensate the 
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HFD induced changes. Moreover, we examined adiposity related to brain volumes 
in chapter 4, where we reported that body mass index (BMI), waist circumference 
(WC), and leptin were negatively associated with total gray matter volume (GMV). 
Moreover, we found that leptin was negatively associated with severe white matter 
hyperintensities (WMH) and presence of lacunes, which indicated a protective 
effect of leptin in relation to CSVD outcomes. Whereas others reported that 
adiposity indicated by the amount of visceral adipose tissue, is positively associated 
with CSVD indicated by microbleeds, lacunes, and WMH (318, 339). Possibly, 
anthropometric measurements like BMI and WC may not be accurate enough to 
indicate specifically visceral adipose tissue. In addition, CSVD progression seems 
to be nonlinear, accelerating over time, and seems to be a highly dynamic process 
(324), which might complicate the over time analyses of the association between 
adiposity and CSVD markers. Moreover, in humans we used 1.5 Tesla MRI images 
to indicate CSVD markers. High resolution images, used in our preclinical research 
(11.7 Tesla), might provide the opportunity to precisely examine microstructural 
changes within the cerebral circulation. Thus, in rodent models we reinforce the 
adverse effects of obesity within cerebrovascular pathology. However, in humans 
more research is necessary to elucidate the effect of obesity on cerebrovascular 
pathology, in specific brain regions and its progression.
White adipose tissue (WAT)
Adiposity seems to be a key inducer of adverse effects on health, and cause of 
dysfunction of numerous types of tissues including the brain (112, 117, 321). WAT 
is a large endocrine organ, secreting hundreds of adipokines, and particularly 
the endocrine activity of WAT can be deregulated in adiposity (77). Adipokines 
contribute to the regulation of appetite and satiety, fat distribution, insulin secretion 
and sensitivity, energy expenditure, endothelial function, inflammation, and blood 
pressure  (427). Therefore, alterations in adipokine secretion may link adiposity 
to its inflammatory, metabolic, and vascular comorbidities (427). Functional 
characterization, in particular of the more recently identified adipokines like 
vaspin, apelin and resistin, is a major task in future adipokine research. 
In mouse models, we found that leptin is not increased in mildly obese mice, whereas 
leptin levels were significantly increased in the obese mice (428)(Chapter 2 and 3). 
In Chapter 4 and 5, we reported that obese individuals have increased leptin levels, 
and women exert a higher level than men. These findings are in coherence with 
findings in literature (77, 389). Moreover, we reported asynchronous results for 
leptin in chapter 4 and 5, for instance leptin was negatively associated with GMV 
in men, whereas it was suggested to be protective in relation to CSVD outcomes in 
men, and dementia in women. These findings might indicate that leptin’s effects in 
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the adiposity-brain-axis are diverse, change with aging and are influenced by sex. 
Notably, leptin levels are mostly determined in blood plasma, which provides an 
accurate indication of metabolic activity. However, leptin signaling within the brain 
depends on transport of leptin across the blood brain barrier, and availability of its 
receptors in specific brain regions (77). Therefore, further research is necessary to 
elucidate the exact function of leptin in specific brain regions, aging and sex.
Adiponectin is a protein hormone, most well-described for modulating 
inflammatory responses, energy expenditure, energy intake and a number of 
metabolic processes, including glucose regulation and fatty acid catabolism in 
the periphery (136-138, 140, 429). In the periphery, adiponectin is released from 
adipose tissue into the blood circulation as full-length trimers, hexamers, high 
molecular weight, multimers, and a globular fraction called globular adiponectin 
(430, 431). In humans, plasma adiponectin levels are, in contrast to most adipokines, 
inversely correlated to an increase in WAT, as well as to surrogate measures such 
as percentage body fat, waist-to-hip ratio and BMI (432, 433). In chapter 4 we 
confirm these findings, nevertheless we found no association between adiponectin 
and brain volumes, CSVD markers or dementia. In addition, leptin and adiponectin 
exert insulin-sensitizing effects, they are considered as important regulators of 
β-cell mass and survival (77, 427). Therefore, both adipokines might influence 
the development insulin resistance, and eventually type 2 diabetes mellitus. The 
mouse studies described in chapter 2 and 3 provide blood glucose and plasma 
insulin levels, however both studies are limited in examining glucose homeostasis. 
Following studies should investigate the functionality of α- and β-cells, glucagon, 
or assess a glucose tolerance test.
Aging
During aging the associations clarifying the adiposity-brain-axis can be rather 
ambiguous. In detail, midlife obesity is associated with reduced GMV and 
greater dementia risk, possibly via impairment of cerebral circulation and/or 
neuroinflammation (3, 343, 351, 368, 374). High adiposity might contribute to 
neurodegenerative and cerebrovascular changes through vascular and metabolic 
pathways (434). However, others reported that in humans that midlife overweight 
and obesity were not associated with infarct-like brain lesions, cerebral microbleeds, 
or dementia compared with normal weight after a mean follow-up of 26.2 years 
(435). In chapter 4, we found that BMI, waist circumference (WC) and leptin are 
negatively associated with GMV in adult men (> 50.0 years). Nevertheless, if obesity 
is included in forecast models prevalence of dementia is estimated to be 9% for the 
United States, 14 % in Australia, and 19% higher in China, in 2050 (436, 437). 
In mid-adult obese rodents, a butyrate supplementation served as preventative for 
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obesity and obesity related co-morbidities (Chapter 3). We indicated in this rodent 
study (Chapter 3) that particularly in midlife inflammatory and cerebrovascular 
mechanisms can be influenced by for instance a butyrate intervention. These 
findings might indicate that midlife obesity can be a susceptible life period in which 
a dietary intervention can beneficially effect obesity and its co-morbidities. 
Additionally, examining aging in the adiposity-brain-axis is complicated by 
sex hormones, which induce sex-specific features in WAT storage. For instance, 
importantly, women differ with respect to distribution of WAT, men tend to accrue 
more WAT within the visceral adipose depots, which has been highly correlated 
to increased cardiovascular risk (438). Women on the other hand, accrue more 
WAT in the subcutaneous depots prior to menopause, a feature associated with 
protection from the negative consequences associated with obesity and the 
metabolic syndrome (438). In detail, after menopause, deposition of adipose tissue 
shifts to favor the visceral adipose depot. This shift is accompanied by a parallel 
increase in metabolic risk reminiscent to that seen in men (438). In this thesis we 
found sex differences in associations between adiposity and brain volumes mainly 
in adult men (> 50.0 years), and between adiposity and dementia particularly in 
older women (>70.0 years) (Chapter 4 and 5). Postmenopausal women may have a 
greater risk of developing dementia than men, perhaps due to changes in leptin and 
brain function due to a fall in endogenous estrogen levels following menopause 
(412). Estrogen seems to protect against adiposity, and it can influence the function 
of adipokines like leptin and adiponectin (439). Moreover, estrogen and leptin can 
have neuroprotective effects on cognition by regulating neurogenesis, hippocampal 
synaptic plasticity, and axonal growth (77). Future studies should elucidate the role 
of sex-hormones in an aging adiposity-brain-axis.
Weight loss in late life is strongly associated with dementia risk. Underweight in 
elderly is strongly associated with increased dementia risk within a 5 year follow up 
(315, 440) (Chapter 5), which might be associated with the presence versus absence 
of prodromal dementia. The biological mechanisms involved in late life weight 
changes and the risk of dementia are not fully understood but might be associated 
with pathophysiological changes in brain areas regulating energy intake, behavioral 
disturbances, and medication (71, 337, 381). Moreover, we found that leptin can 
be differently associated with dementia odds than BMI in elderly (Chapter 5). 
This might indicate that the role of leptin changes during aging. Our findings 
are supported by studies reporting that higher levels of leptin are prospectively 
associated with lower odds of dementia or mild-cognitive impairment in elderly 
(360, 414, 415). Moreover, plasma leptin levels have been positively correlated with 
GMV in various brain regions including the hippocampus, and high leptin levels 
might protect against age-related cognitive decline in an elderly population study 
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(355). A study of Bonda et al. revealed that leptin signaling is deregulated in the 
degenerating hippocampal neurons in patients with Alzheimer’s disease (AD), 
which may indicate neuronal leptin resistance in AD (356). Metabolic dysregulation 
may accompany or promote late-life alternations in leptin levels and dementia 
(416). Thereby, leptin might play a pivot role in an aging adiposity-brain-axis, 
and possibly by affecting satiety, glucose homeostasis, inflammatory processes, 
vascular function, and memory formation (112, 117, 321, 357-360). A limitation in 
human studies is that the interpretation and comparing epidemiological findings 
is rather complicated as a study population of people born in 1930 exert different 
anthropometric features as individuals born in 1990, plausibly due to changes 
dietary habits, socioeconomic environment, and scientific and technological 
progress. 
Thus, obesity in midlife most likely forecasts a higher dementia risk in late life, 
although in elderly weight loss might moreover indicate presence of prodromal 
dementia. Future studies could elucidate the progression of structural brain changes 
affected by adiposity in aging, by plotting for example GMV against an obese and 
lean population over a life period.
Diets
High fat diets (HFDs) are regularly used to elicit changes in body composition 
like provoking adiposity, inflammation, non-alcoholic fatty liver disease (NALFD), 
high level of circulating triglycerides and cholesterol, and cognitive deficits (441, 
442). We confirm these effects of a HFD in chapter 2 and 3. The duration of HFD 
feeding is an important factor to consider concerning aim of the study and mouse 
model. As for instance, in a LDLr-/- mouse model, overweight develops after 6-10 
weeks on a 24% w/w HFD, and the first structural brain changes are observed after 
about 12 weeks on HFD and it requires about 24-32 weeks to develop cognitive 
impairment. Male mice are generally more sensitive to develop obesity on HFD 
than female mice. In addition, genetic variation and modification in mouse models 
can affect metabolic function, and therefore the effects of HFD exposure may differ 
between mouse models. In most studies on diet-induced obesity, mice are fed on a 
HFD for 8–15 weeks (421). 
In severe obese individuals the standard lifestyle recommendations fail, or is 
not compatible with modern life routines. Therefore, alternative strategies for 
intervention are urgently required. Preventive nutritional strategies during critical 
periods in life seem promising to reduce the risk of obesity development. For 
instance, omega-3 fatty acids are able to prevent body weight gain, hepatic lipid 
accumulation by inducing hepatic fatty acid oxidation (421, 443, 444). We revealed 
that the intake of LCPUFAs, ARA and DHA, in early life can protect against 
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HFD-induced-obesity in late life (Chapter 2). In children daily consumption 
of DHA and eicosapentaenoic acid (EPA) improved anthropometric and lipid 
parameters (27). These findings confirm that ARA and DHA dietary intake in early 
life strengthens the ability to cope with an obesogenic diet. In chapter 3 we found 
that butyrate, a short chain fatty acid (SCFA), restores HFD-induced obesity on 
metabolic, cerebrovasculature and cognitive function. Possible mechanisms by 
which ARA, DHA and butyrate can protect or restore HFD-induced obesity and 
co-morbidities is still incomplete. Although, it has been reported that ARA and 
DHA intake results in variations in adipocyte differentiation, whereby storage of 
WAT can be affected (262). Moreover, DHA and ARA are the two most abundant 
LCPUFAs in the brain, and are essential to support optimal brain and visual system 
development (204, 205). Butyrate has anti-inflammatory properties, contributes 
to fatty acid oxidation, and can induce a switch from lipid synthesis to lipid 
utilization (298, 308). In addition, butyrate most likely affects cognitive function 
via enhancing histone acetylation by inhibiting histone deacetylase (283). Dynamic 
changes in histone acetylation have been linked to the genetic programming 
required for memory formation (283). Additionally, adiposity can be affected by 
the gut microbiome through energy harvesting and lipid storage by the bacteria. 
Moreover, butyrate is a product of bacterial fermentation of mainly indigestible 
plant polysaccharides and resistant starch in the colon, and obese individuals have a 
decreased level of butyrate producing microbiota (23). Furthermore, analysis of the 
gut microbiome revealed pronounced changes in composition upon HFD feeding 
(Chapter 3). These HFD induced changes were very consistent with observations 
made by others (312). In line with observations made in obese humans which exhibit 
decreased levels of butyrate-producing bacteria compared to lean individuals (24), 
we found HFD induced in Clostridium XIVa abundancy (Chapter 3). Moreover, 
the pronounced difference between the microbiome of mice fed a control diet or 
fed a HFD made it difficult to discriminate the specific effects of butyrate (Chapter 
3). However, in literature it was reported that both butyrate and omega-3 fatty 
acids modify microbiome composition, and the expression of anti-inflammatory 
compounds (445-447). Thereby, butyrate and DHA are able to affect adiposity by 
modifying microbiome composition. Thus, fatty acids like DHA and butyrate, exert 
a moreover protective effect in adiposity and its co-morbidities. Nevertheless, it has 
to be taken into account that dietary interventions might provoke slightly altered 
effects in other mouse models as their metabolic function may differ due to genetic 
modification.
In humans, LCPUFAs like ARA and DHA are added in milk formula’s and they 
are beneficially affecting the development of infants (448). In addition, in adults 
LCPUFAs improve vascular endothelial function and can reduce blood pressure, 
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circulating lipids, and inflammatory processes (449, 450). We indicated that SCFAs, 
like butyrate, may serve as potential preventative for obesity and obesity related 
diseases (Chapter 3). However, up till now it is rather difficult for obese individuals 
to obtain a relatively high concentration of butyrate within their blood plasma. 
Some adversities to overcome are for example the distinctive odor of butyrate, 
and relatively low uptake of butyrate in the blood circulation when consuming 
fiber rich diets (451). Nevertheless, Van der Beek et al. implied that rectal butyrate 
administration was safe at a dose of 100 mmol sodium butyrate/L, and that it led 
to higher portal butyrate concentrations compared with placebo (452). Future 
research could address the effectiveness of a lower concentration of butyrate and/
or capsules that release butyrate within the intestine. 
Concluding remarks of this thesis research
Overall, in this thesis we clearly demonstrate a link between adiposity and brain 
function. Animal studies have the potential to examine biological mechanisms 
and dietary interventions within the adiposity-brain-axis in great detail. Moreover, 
with this thesis we have furthered the understanding of biological mechanisms by 
which adiposity can affect brain function, e.g. via adipokines like leptin or affecting 
cerebral circulation. However, it seems to be a highly interactive and multi-factorial 
process, which is clearly altered by sex and during aging. Therefore, future research 
should account for age and sex-hormones while examining the adiposity-brain-axis. 
Moreover, we underline the role of diets in health. Firstly, intake of LCPUFAs (ARA 
and DHA) in early life prevents WAT accumulation, improves gut microbiome and 
preserves brain function. Secondly, a butyrate intervention, and plausible the intake 
of indigestible fibers (butyrate is a product of bacterial fermentation of indigestible 
fibers), can counteract HFD-induced adverse health effect in midlife in adiposity, 
gut microbiome, cerebrovasculature, liver and brain function. Thereby, balanced 
diets containing undigested fibers and LCPUFAs have a crucial role in attenuating 
the genesis of adiposity and it co-morbidities throughout lifespan.
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Summary
Worldwide, obesity has reached epidemic proportions, and each year obesity or 
obesity-related-diseases lead to the death of 2.8 million adults. Obesity has an 
undefined aetiology, but is generally caused by imbalance of energy intake versus 
energy output. This imbalance results in excessive, mainly white adipose tissue 
(WAT) accumulation, adiposity, which eventually may have an adverse effect on 
human health, such as cardiovascular disease, type 2 diabetes mellitus and cognitive 
impairment. The aim of the research presented in this thesis was to elucidate 
the adiposity-brain-axis involving dietary fatty acids (arachidonic acid (ARA), 
docosahexaenoic acid (DHA) and butyrate), (cerebro)vasculature, adipokines, and 
the effect of aging on these processes.
Chapter 1 provides the background information for this thesis research, including 
the role of diets in the progression, and contrarily the prevention, of adiposity. 
Moreover, we discuss two pathways via which adiposity might affect brain 
structure, function and cognition with emphasis on the (cerebro)vascular pathway 
and adipokines. In short, diets with a high content of saturated fat (HFD) or high 
fat and high carbohydrates (HFHC), are considered to be important contributing 
factors of obesity, whereas dietary interventions containing adequate levels of 
LCPUFAs, butyrate or even fiber rich diets, could contribute to the decline of 
adiposity. Moreover, we hypothesize that adiposity can induce (cerebro)vascular 
changes such as arterial stiffness, inflammation and hypoperfusion, which can 
subsequently disrupt brain structure and function, and increase the risk for 
cognitive impairment and dementia. Lastly, we speculate that adipokine release may 
be dysregulated in adiposity, possibly because the adipose tissue may be ‘diseased’. 
Since neurodegenerative and vascular processes observed in dementia affect 
several brain regions and nuclei, the action of adipokines might be altered during 
neurodegenerative and vascular events, and may even feedback to contribute to 
neurodegeneration.
In the first experimental work, described in chapter 2, we examined the effect of 
early life dietary long chain polyunsaturated fatty acids (LCPUFAs, ARA and DHA) 
intake in mild-obese transgenic ApoE3*Leiden mice. A broad and multidisciplinary 
experimental approach was used to examine energy metabolism, brain structure, 
cerebral circulation, and cognition. We found that a HFD diet causes adverse 
structural brain and metabolic adaptations in mildly obese mice, like a decrease 
in functional connectivity and gray matter integrity, and an increase in cholesterol 
and triglycerides levels. Importantly, most of these alterations due to HFD can be 
averted by dietary intake of ARA and DHA for 8 weeks early in life, which supports 
metabolic flexibility and cerebral integrity later in life. 
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In chapter 3 a severe mouse model of obesity, low-density lipoprotein receptor 
knock-out Leiden (LDLr-/-) mouse, have been examined for the development of 
HFD-induced-obesity, inflammation within WAT, increased fat storage within 
the liver, increased systolic blood pressure, and cerebral hypoperfusion (Chapter 
3). Subsequently, we aimed to examine the preventive abilities of short chain 
fatty acid, butyrate in obese LDLr-/- male mice. We found that butyrate restored 
HFD-induced-obesity parameters towards normal levels in two months in 
mid-adult obese mice, for instance it restored body weight, neuroinflammation, 
liver steatosis, cerebral blood flow and functional connectivity. Additionally, we 
found that a HFD can lower the variance the gut microbiome, and thereby a HFD 
can affect adiposity through energy harvesting and lipid storage by the bacteria. 
Moreover, butyrate could modify microbiome composition, nevertheless the 
pronounced effects of HFD made it difficult to discriminate the specific effects of 
butyrate. Furthermore, we suggest that butyrate may have potential in prevention 
and treatment of midlife obesity.
In chapter 4 and 5 we aimed to analyze associations concerning the 
adiposity-brain-axis in humans. In the RUN DMC study (Chapter 4), we found 
that adiposity indicators, body mass index (BMI), waist circumference (WC) and 
leptin are negatively associated with gray matter volume (GMV) in men diagnosed 
with cerebral small vessel disease (CSVD) at baseline. BMI and WC were also 
inversely associated with hippocampal volume in men. At follow-up, 9 years later, 
cross-sectional analyses showed inverse associations between BMI and GMV; and 
WC and hippocampal volume, particularly in men. In relation to CSVD outcomes, 
the metabolic adiposity indicator, leptin, was protective in men. In particular, the 
highest quartile of leptin (compared to the first quartile) was inversely associated 
with severe white matter hyperintensities, the presence of any lacunes and the 
presence of at least one component of CSVD. These findings indicate that adiposity 
measures, both anthropometric and metabolic were differentially associated with 
brain volumes and CSVD, and by sex. These findings suggest an Alzheimer-vascular 
spectrum associated with adiposity, a known marker of both neurodegeneration 
and vascular risk, that both influences and is influenced by brain pathologies 
associated with dementia. 
In chapter 5, we examined in older Swedish adults individuals participating in the 
Gothenburg studies. These Gothenburg studies provided us a 10-year prospective 
population-based study of 70 years and older inhabitants of Gothenburg, Sweden. 
Subsequently, we analyzed if anthropometric parameters as BMI and waist-hip 
ratio, and serum adipokines levels like adiponectin and leptin could predict 
dementia risk in older Swedish adults over a 5 and 10 year period. In addition, we 
examined whether these associations are different between older men and women. 
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We found that in late-life, anthropometric and metabolic adiposity measures 
appear to be differentially associated with dementia risk in women aged 70 years 
and older (Gothenburg). In detail, while BMI and leptin levels are highly positively 
correlated, our results show that their association with dementia at age ≥ 70 years, 
is asynchronous. Leptin is associated with decreased dementia risk, whereas low 
BMI (<20 kg/m2) predicted an increased dementia risk over a 5 year period.
In chapter 6, we provide an extensive discussion of the research findings summarized 
above, and furthermore we propose follow-up studies are needed to address the 
questions that have arisen from our work. The most important conclusions of 
this thesis research are: 1) A clear link between adiposity and brain function. 2) 
The potential of animal studies to examine biological mechanisms and dietary 
interventions within the adiposity-brain-axis in great detail. 3) Intake of LCPUFAs 
in early life prevents WAT accumulation, and preserves brain function. 4) Butyrate 
intervention and plausible the intake of indigestible fibers (butyrate is a product 
of bacterial fermentation of indigestible fibers), can counteract HFD-induced 
adverse health effect in midlife in adiposity, gut microbiome, cerebrovasculature, 
liver and brain function. 5) The adiposity-brain-axis is a highly interactive and 
multi-factorial process, which is clearly altered by sex and during aging. Overall, 
we think that the research described in this thesis has furthered the understanding 
of biological mechanisms by which adiposity can affect brain function. Thereby, 
balanced diets containing undigested fibers and LCPUFAs have a crucial role in 
attenuating the genesis of adiposity and it co-morbidities throughout lifespan.
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Nederlandse Samenvatting
Obesitas is uitgegroeid tot een wereldwijde epidemie, en elk jaar resulteren obesitas 
of obesitas-gerelateerde-ziekten in de dood van 2.8 miljoen volwassenen. Obesitas 
heeft onbepaalde etiologie, maar wordt over het algemeen veroorzaakt door een 
disbalans tussen energie inname en energie verbranding. Deze disbalans resulteert 
in extreme vetopslag van vooral het zogenaamde witte vet. Deze extreme vetopslag 
wordt ook wel adipositas of vetzucht genoemd. Adipositas heeft een negatieve 
invloed op de gezondheid en kan uiteindelijk bijdragen aan het ontwikkelen 
van ziekten, zoals bijvoorbeeld cardiovasculaire ziekten, type 2 diabetis mellitus 
of zelfs cognitieve achteruitgang en dementie. In het onderzoek beschreven in 
dit proefschrift hebben we onderzocht of de adipositas-brein-as beïnvloed kan 
worden door vetzuren in het dieet (arachidonzuur (ARA), docosahexaeenzuur 
(DHA) en butyraat) en daarnaast, of er in deze as een rol is weggelegd voor de 
hersendoorbloeding en adipokinen. De laatst genoemde, adipokinen zijn hormonen, 
eiwitten en cytokinen geproduceerd door het witte vetweefsel. Als laatste zullen we 
onderzoeken wat de invloed is van veroudering op de adipositas-brein-as.
Hoofdstuk 1 schetst de achtergrond van het onderzoek beschreven in dit 
proefschrift. We bespreken in dit hoofdstuk de rol van vetzuren in het ontstaan en 
tegengaan van adipositas. Zo is het bekend dat diëten met een hoge concentratie 
aan verzadigd vet en/of in combinatie met veel koolhydraten een belangrijke rol 
spelen in het veroorzaken van obesitas. Als tegengewicht, zijn er vetzuren die 
de ontwikkeling adipositas kunnen tegenwerken, voorbeelden zijn lange-keten-
meervoudig-onverzadigde-vetzuren (LCPUFAs) en korte-keten-vetzuren (SCFAs, 
butyraat). De SCFAs kunnen worden gevormd door bacteriën in de darmwand 
wanneer deze bacteriën vezels verteren. Daaropvolgend bediscussiëren we via 
welke wegen adipositas de brein functie en cognitie zou kunnen beïnvloeden. Eén 
van de mogelijke wegen richting het brein zou kunnen zijn door het aantasten van 
de hersendoorbloeding, namelijk onder andere door verstijving en/of vernauwing 
van de vaten rondom het brein en ontstekingen in het brein. Deze veranderingen 
in de hersendoorbloeding kunnen daaropvolgend een negatieve invloed hebben 
op zenuwcellen in het brein, wat kan resulteren in cognitieve achteruitgang of zelfs 
dementie. Een andere weg richting het brein is vanuit het witte vetweefsel, zo zou 
de adipokinen productie verstoord kunnen zijn. Adipokinen zijn betrokken in 
vele biologische processen en kunnen ook op vele hun invloed uitoefenen. Als de 
productie van deze adipokinen verstoord is of uit balans doordat er extreem veel 
vetweefsel is, dan zouden zij neurodegeneratieve en vasculaire processen kunnen 
beïnvloeden wat uiteindelijk zou kunnen leiden tot cognitieve achteruitgang en 
dementie. 
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In het eerste experimentele onderzoek beschreven in hoofdstuk 2, onderzochten wij 
of de inname van de LCPUFAs, ARA en DHA in het vroege leven een beschermend 
effect kon hebben in muizen (ApoE3*Leiden). Deze muizen kregen drie weken na 
hun geboorte voor acht weken een dieet met de LCPUFAs, daaropvolgend kregen 
deze muizen voor 12 weken een hoog vet dieet (HFD). Om de effecten van deze 
diëten te onderzoeken hebben we een veelzijdige aanpak gebruikt om onder andere 
veranderingen in energie metabolisme, hersendoorbloeding, het brein en cognitie 
te kunnen analyseren. Uiteindelijk vonden wij dat een dieet met veel verzadigde 
vetzuren (hoog vet dieet; HFD) aanpassingen veroorzaakten op metabool vlak en 
in het brein, zoals bijvoorbeeld een toename van cholesterol en triglyceriden in het 
bloed, vermindering in verbindingen tussen hersengebieden en afname in grijze 
stof. Ook konden we concluderen dat de inname van ARA en DHA in het vroege 
leven bescherming biedt tegen de meeste veranderingen veroorzaakt door het HFD 
op latere leeftijd. Deze bevinding benadrukt de metabole flexibiliteit en cerebrale 
integriteit in het latere leven. 
In hoofdstuk 3 beschrijven we een onderzoek met als doel om het effect van 
korte-keten-vetzuur, butyraat te achterhalen in middelbare en oudere obese 
muizen. In dit onderzoek gebruikten we muizen die het gen voor de receptor van 
de lage-dichtheid-lipoproteïne missen, deze zogenaamde LDLr-/-.Leiden muizen. 
Deze muizen ontwikkelen op een HFD een zware vorm van obesitas. In dit 
onderzoek waren we met name geïnteresseerd in de ontwikkeling van adipositas, 
ontsteking van het witte vetweefsel, opslag van vet in de lever, bloeddruk en 
de cerebrale doorbloeding. We vonden dat een butyraat-interventie van twee 
maanden de negatieve effecten van een HFD voor een groot deel terug kon brengen 
naar normale controle waarden, en dit met name in de muizen van middelbare 
leeftijd. Daarbij ontdekten we dat een HFD de variatie verlaagt van bacteriën in 
de darm, en daarmee kan een HFD effect hebben op het verkrijgen van energie 
en vetopslag door bacteriën. Als laatste, vonden we dat butyraat de samenstelling 
van darmbacteriën kan veranderen, ondanks dat het lastig was om het effect van 
butyraat te onderscheiden van de effecten van een HFD op het darm bacteriën. We 
concludeerden uit dit onderzoek dat butyraat een belangrijke rol kan spelen in het 
tegenwerken van de ontwikkeling van adipositas op middelbare leeftijd.
Wij beschrijven in hoofdstuk 4 en 5 onderzoeken uitgevoerd in mensen. In 
beide hoofdstukken hebben we met statische analysemodellen onderzocht of en 
hoe adipositas parameters zijn geassocieerd met het brein en dementie, om zo 
de adipositas-brein-as duidelijker te kunnen schetsen in mensen. De adipositas 
parameters die we analyseerden waren BMI, buikomvang, leptine en adiponectine. 
In hoofdstuk 4 analyseerden we in de RUN DMC studie, body mass index (BMI), 
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buikomvang (WC), leptine en adiponectine (parameters voor adipositas), en in het 
brein bekeken we de afwijkingen aan de vaten, en grijze en witte stof volumes. De 
RUN DMC studie bestaat uit mannen en vrouwen die gediagnosticeerd zijn met 
ziekte aan de kleine vaten in het brein (CSVD). We vonden dat BMI, WC en leptine 
negatief geassocieerd zijn met volume van de grijze stof, met name in mannen 
(>50.0 jaar). Dit indiceert dat adipositas geassocieerd is met een lager grijze stof 
volume in mannen. Daarbij vonden we dat leptine een beschermend effect kan 
hebben in mannen, met betrekking tot de vasculaire parameters in het brein. In 
detail, leptine was negatief geassocieerd met verlies van integriteit van de wite stof 
(zogenaamde white matter hyperintensities) en de aanwezigheid van lacunes in 
het brein, welke beiden parameters zijn voor CSVD. Deze bevindingen indiceren 
dat parameters voor adipositas verschillend zijn geassocieerd met brein volume, 
vasculaire parameters, en geslacht. In hoofdstuk 4 bediscussiëren we dat adipositas 
invloed kan hebben op hersenaandoeningen, zoals bijvoorbeeld verminderde grijze 
stof, en dat deze hersenaandoeningen zijn sterk geassocieerd met dementie. 
In hoofdstuk 5 wordt een Zweeds onderzoek, de Gothenburg cohort studies 
beschreven. Deze studies bestaan uit Zweedse ouderen, man en vrouw, van 70 
jaar en ouder. In deze studie analyseerden we of parameters voor adipositas (BMI, 
buik-heup-ratio, leptine en adiponectine) geassocieerd zijn met dementie over een 
periode van tien jaar. Daarbij analyseerden we ook of er een verschil was tussen 
mannen en vrouwen. Wij vonden dat in oudere vrouwen (>70.0 jaar), leptine en 
BMI verschillend geassocieerd zijn met het risico op dementia binnen 5-jaar. Dit 
terwijl je verwacht dat leptine en BMI dezelfde associatie hebben omdat ze sterk 
met elkaar gecorreleerd zijn. Zo is leptine is geassocieerd met een verminderde 
kans op dementie, terwijl een lage BMI (<20 kg/m2) een verhoogd risico geeft om 
dementie te ontwikkelen binnen 5 jaar. 
We bediscussiëren al onze resultaten in hoofdstuk 6, en daarnaast stellen 
we mogelijke andere toekomstige onderzoeken voor die vragen zou kunnen 
beantwoorden ontstaan uit het onderzoek beschreven in dit proefschrift. Ook 
bespreken we de belangrijkste conclusies van dit proefschrift, deze zijn: 1) er is een 
duidelijk verband tussen adipositas en brein functie. 2) Onderzoek in muismodellen 
biedt de kans om biologische processen en dieet interventies betrokken in de 
adipositas-brein-as in diepgaand detail te onderzoeken. 3) De inname van LCPUFAs 
in het vroege leven beschermt tegen adipositas, en behoudt van een gezonde brein 
functie. 4) Een butyraat interventie, en mogelijk de inname van vezels, kan de 
negatieve effecten van een HFD-dieet tegenwerken met name op middelbare leeftijd 
op het gebied van darm microbioom, hersendoorbloeding, lever en brein functie. 
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5) De adipositas-brein-as is een interactieve en multifactoriële as, die zeker wordt 
beïnvloed door geslacht en gedurende veroudering. Al met al, denken wij dat het 
onderzoek beschreven in dit proefschrift bijdraagt aan een verbeterd inzicht in de 
biologische mechanismen betrokken in de adipositas-brein-as. Uitgebalanceerde 
vezelrijke diëten met LCPUFAs kunnen een belangrijke rol spelen in het tegengaan 
van adipositas en de ontwikkeling van obesitas-gerelateerde-ziekten. 
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List of Abbreviations
AC  Auditory cortex
AD  Alzheimer’s disease
ADAS-Cog Alzheimer’s disease assessment scale-cognitive subscale 
AgRP  Agouti-related peptide 
ANOVA Analysis of variance
APOC1  Apolipoprotein C-I
APOE  Apolipoprotein E
APOE3  Apolipoprotein E3
ApoE3*Leiden Apolipoprotein E3 Leiden
APOEε4 Apolipoprotein E ε4 allele
ARA  Arachidonic acid
ASL  arterial spin labeling
BBB  Blood brain barrier
BMI  Body mass index
BOLD  Blood oxygen level-dependent 
CA1  Cornu Ammonis area 1,
CART  cocaine and amphetamine-regulated transcript 
CBF  Cerebral blood floow
cDNA  Complementary deoxyribonucleic acid
CM  Custom made
CNS  Central nervous system
CPRS  Comprehensive psychiatric rating scale
CRP  C-reactive protein
CSF  Cerebrospinal fluid
CSVD  Cerebral small vessel disease
CT  Cycle threshold
CVD  Cardiovascular disease
DH  Dorsal hippocampus
DHA  Docosahexaenoic
DNA  Deoxyribonucleic acid
DSM-III-R Diagnostic and statistical manual of mental disorders 3rd edition  
  revised 
DTI  Diffusion tensor imaging
ELISA  Enzyme-linked immunosorbent assay
EPA  Eicosapentaenoic acid
FA  Fractional anisotropy
FAIR  Flow-sensitive alternating inversion recovery 
FC  Functional connectivity
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FFAR2  Free fatty acid receptor 2
FFAR3  Free fatty acid receptor 3 
fMRI  Functional magnetic resonance imaging
FW  Forward
GAPDH Glyceraldehydes 3-phosphate dehydrogenase 
GLUT-1 Glucose transporter 1
GMV  Gray matter volume
H70  Gerontological and geriatric population studies 
HDAC  Histone deacetylase 
HDL  High density lipoprotein
HFD  High fat diet
HFDB  High fat diet enriched with butyrate
HFHC  High fat and high carbohydrates diet
HMW  High molecular weight
HV  Hippocampal volume
IBA-1  Ionized calcium binding adapter molecule-1
ICV  Intracranial volume
IL-1β  Interleukin-1 beta
IL-6  Interleukin-6
InsulinR Insulin receptor
IVC  Individually ventilated cages
LCPUFAs Long-chain polyunsaturated fatty acids
LDL  Low-density lipoprotein 
LDL  Low density lipoprotein
LDLr  Low-density lipoprotein receptor 
LDLr-/- Low-density lipoprotein receptor knock-out Leiden 
LTP  Long term potentiation
m.o.  Months old
MC  Motor cortex
MCP-1  Monocyte chemotactic protein-1
MD  Mean diffusivity
MED  Minimum entropy decomposition 
MINI  Mini international neuropsychiatric interview 
MMSE  Mini–Mental State Examination 
MRI  Magnetic resonance imaging
mRNA  Messenger ribonucleic acid
MWM  Morris water maze
n  Group size
NALFD Non-alcoholic fatty liver disease
NaN3  Sodium azide
NE  North-East
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NE  Not estimable
NMDA  N-methyl-D-aspartate
NPY  Neuropeptide Y
ObRA  Leptin receptor A
OBRB  Leptin receptor B
OF  Open field
OR  Odds ratio
ORT  Object recognition test
PAI-1  Plasminogen activator inhibitor
PBS  Phosphate-buffered saline 
pCVD  Premature cardiovascular disease
PET  Positron emission tomography
PPARγ  Peroxisome profilerator-activated receptor-γ
PPSW  Prospective population study of women
PRIME  Preclinical imaging centre
PSD-95  Postsynaptic density protein-95 
Q  Quartile
qRT-PCR Quantitative real time polymerase chain reaction
REV  Reverse
RNA  Ribonucleic acid
ROI  Region of interest
rRNA  Ribosomal ribonucleic acid
rsfMRI  Resting state functional magnetic resonance imaging
RUN DMC Radboud University Nijmegen Diffusion tensor and Magnetic  
  resonance imaging Cohort
SAA  Serum amyloid A
SBP  Systolic blood pressure
SCFAs  Short chain fatty acids
SD  Standard deviations
SEM  Standard error of mean
SPF  Specific pathogen free
SSC  Somatosensory cortex
STRIVE Strategies and therapies for reducing ischemic and vascular events
T2DM  type two diabetes mellitus
TBV  Total brain volume
TIA  Transient ischemic attack
TNF-α  Tumor necrosis factor alpha
TNO  Toegepast-natuurwetenschappelijk onderzoek
VC  Visual cortex
VCAM-1 Vascular cell adhesion molecule 1 
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VEGF  Vascular endothelial growth factor
VEGF-A Vascular endothelial growth factor A
VH  Ventral hippocampus
VLDL  Very low density lipoprotein 
w/w  Weight by weight
WAT  White adipose tissue
WC  Waist circumference
WHR  Waist hip ratio
WMH  White matter hyperintensities
WML  White matter lesion
WMV  White matter volume
α-MSH  Alpha-melanocyte-stimulating hormone
β (95% C.I.) Beta-coefficients and 95% confidence Intervals
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For a successful research Institute, it is vital to train the next generation of young 
scientists. To achieve this goal, the Donders Institute for Brain, Cognition and 
Behaviour established the Donders Graduate School for Cognitive Neuroscience 
(DGCN), which was officially recognised as a national graduate school in 2009. 
The Graduate School covers training at both Master’s and PhD level and provides 
an excellent educational context fully aligned with the research programme of the 
Donders Institute. 
The school successfully attracts highly talented national and international students 
in biology, physics, psycholinguistics, psychology, behavioral science, medicine 
and related disciplines. Selective admission and assessment centers guarantee the 
enrolment of the best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD 
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worldwide, e.g. Stanford University, University of Oxford, University of Cam-
bridge, UCL London, MPI Leipzig, Hanyang University in South Korea, NTNU 
Norway, University of Illinois, North Western University, Northeastern Universi-
ty in Boston, ETH Zürich, University of Vienna etc.. Positions outside academia 
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development. Fewer graduates stay in a research environment as lab coordinators, 
technical support or policy advisors. Upcoming possibilities are positions in the IT 
sector and management position in pharmaceutical industry. In general, the PhDs 
graduates almost invariably continue with high-quality positions that play an im-
portant role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please 
visit:
http://www.ru.nl/donders/graduate-school/phd/
